Rakkude paljunemist soodustav AKT signaalirada kui potentsiaalne kasvajavastase ravi sihtmärk by Mäemets-Allas, Kristina
1
Tartu 2016
ISSN 1024-6479
ISBN 978-9949-77-143-1
DISSERTATIONES 
BIOLOGICAE 
UNIVERSITATIS 
TARTUENSIS
294
 
K
R
ISTIN
A
 M
Ä
EM
ETS-A
LLA
S 
Studies on cell grow
th prom
oting A
K
T signaling pathw
ay – a prom
ising anti-cancer drug target
KRISTINA MÄEMETS-ALLAS
Studies on cell growth promoting 
AKT signaling pathway – a promising  
anti-cancer drug target
DISSERTATIONES BIOLOGICAE UNIVERSITATIS TARTUENSIS 
294 
  
DISSERTATIONES BIOLOGICAE UNIVERSITATIS TARTUENSIS 
294 
 
 
 
 
 
 
 
 
 
 KRISTINA MÄEMETS-ALLAS 
 
 
Studies on cell growth promoting  
AKT signaling pathway – a promising  
anti-cancer drug target 
 
  
Department of Cell Biology, Institute of Molecular and Cell Biology, Uni-
versity of Tartu, Estonia 
 
Dissertation was accepted for the commencement of the degree of Doctor of 
Philosophy (in Cell Biology) on June 8, 2016 by the Council of the Institute of 
Molecular and Cell Biology, University of Tartu, Estonia 
 
Supervisor: Viljar Jaks, PhD, MD 
 Senior Researcher 
 Department of Cell Biology 
 Institute of Molecular and Cell Biology 
 University of Tartu 
 Estonia 
 
Opponent:  Juha Tapio Klefström, PhD 
 Research Director and Vice Director 
 Research Programs Unit and Translational Cancer Biology 
 Medical Faculty  
 University of Helsinki 
 Finland 
 
Commencement: Room No. 105, 23B Riia St., Tartu, on August 26, 2016, at 
10:15 am. 
 
The publication of this dissertation is granted by the Institute of Molecular and 
Cell Biology. 
 
 
 
 
 
 
 
 
 
ISSN 1024-6479 
ISBN 978-9949-77-143-1 (print)  
ISBN 978-9949-77-144-8 (pdf) 
 
 
 
 
University of Tartu Press 
www.tyk.ee 
Copyright: Kristina Mäemets-Allas, 2016
5 
TABLE OF CONTENTS 
LIST OF ORIGINAL PUBLICATIONS .......................................................  7 
ABBREVIATIONS ........................................................................................  8 
INTRODUCTION ..........................................................................................  11 
LITERATURE OVERVIEW .........................................................................  12 
1.  AKT kinases – classification and structure ..........................................  12 
2.  AKT activation and modification .........................................................  14 
2.1.  AKT1 phosphorylation at Thr308 and Ser473 .............................  14 
2.2.  Alternative AKT modifications ....................................................  16 
3.  AKT signaling pathway .......................................................................  18 
3.1.  AKT regulates cell survival and apoptosis ...................................  19 
3.2.  AKT regulates cell cycle progression and proliferation ...............  21 
3.3.  AKT regulates cell growth and metabolism .................................  23 
3.4. AKT regulates angiogenesis .........................................................  26 
4.  AKT and cancer ...................................................................................  27 
4.1.  AKT signaling in cancer ...............................................................  27 
4.2.  AKT and cancer stem cells ...........................................................  28 
5.  Protein-protein interaction inhibitors ...................................................  29 
6.  AKT inhibitors .....................................................................................  31 
RESULTS 
Objectives of the study ...................................................................................  33 
1.  A Novel Inhibitor of AKT1–PDPK1 Interaction Efficiently  
Suppresses the Activity of AKT Pathway and Restricts Tumor  
Growth In Vivo (REF I)........................................................................  33 
1.1.  Screening for the inhibitors of AKT1 and PDPK1 interaction .....  33 
1.2.  NSC156529 reduces AKT phosphorylation level and inhibits  
AKT1-PDPK1 endogenous interaction ........................................  34 
1.3.  AKT1-PDPK1 interaction inhibitor NSC156529 suppresses  
the activity of AKT downstream targets and cancer  
cell proliferation in vitro ...............................................................  35 
1.4.  AKT1-PDPK1 interaction inhibitor NSC156529 suppresses  
the cell proliferation and induces expression of differentiation 
markers in vivo .............................................................................  36 
1.5.  NSC156529 interacts preferentially with PDPK1 ........................  37 
2.  The inhibition of AKT-PDPK1 interaction efficiently suppresses  
the growth of murine primary liver tumor cells (REF II) ....................  37 
2.1.  Increased activity of liver tumor-associated pathways  
in K07074 .....................................................................................  38 
2.2.  AKT and Notch inhibitors efficiently suppress the growth  
of K07074 cells ............................................................................  39 
6 
3.  Activated growth factor signaling and increased phosphorylation  
of AKT in small blood vessels provide supportive environment  
for Dupuytren’s contracture pathogenesis (REF III) ............................  40 
3.1.  Blood vessels in the DC contain proliferating cells and  
endothelial cells with activated phenotype ...................................  40 
3.2.  The blood vessels in DC tissue contain cells with activated  
AKT signaling ..............................................................................  41 
DISCUSSION ................................................................................................  42 
SUMMARY ...................................................................................................  45 
SUMMARY IN ESTONIAN .........................................................................  47 
REFERENCES ...............................................................................................  49 
ACKNOWLEDGEMENTS ...........................................................................  72 
PUBLICATIONS ...........................................................................................  73 
CURRICULUM VITAE ................................................................................  128 
ELULOOKIRJELDUS ...................................................................................  130 
 
  
7 
LIST OF ORIGINAL PUBLICATIONS 
The current thesis is based on the following original publications, which will be 
referred to by their Roman numerals in the text: 
 
I. Mäemets-Allas, K., Viil, J., Jaks, V. (2015) A Novel Inhibitor of AKT1-
PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway 
and Restricts Tumor Growth In Vivo. Mol Cancer Ther. 14(11):2486–96 
 
II. Mäemets-Allas, K., Belitškin, D., Jaks, V. (2016) The inhibition of AKT-
PDPK1 interaction efficiently suppresses the growth of murine primary 
liver tumor cells. Biochem Biophys Res Commun. 474(1):118–125 
 
III. Viil, J., Maasalu, K., Mäemets-Allas, K., Tamming, L., Lõhmussaar, K., 
Tooming, M., Ingerpuu, S., Märtson, A., Jaks, V. Laminin-rich blood vessels 
display activated growth factor signaling and act as the proliferation centers 
in Dupuytren’s contracture. (2015) Arthritis Res Ther. 17(1):144–153 
 
 
The articles listed above have been reprinted with the permission of the copy-
right owners. 
 
My contribution to these articles: 
REF I  –  designed and performed the experiments, analyzed the data and 
wrote the manuscript 
REF II  –  designed and performed the experiments, analyzed the data and 
wrote the manuscript 
REF III  –  designed and performed the gene expression analysis, analyzed the 
data, revised the manuscript 
  
8 
ABBREVIATIONS 
ABC  ATP binding cassette 
ACK1  activated CDC42 kinase 1 
ACL  ATP citrate lyase 
ALDH1 aldehyde dehydrogenase 1  
ALT  alanine aminotransferase 
APAF-1 apoptotic protease activating factor 1 
AS160  AKT substrate of 160 kDa 
AST  aspartate aminotransferase 
ATM  ataxia telangiectasia mutant 
ATRA  all-trans-retinoic-acid 
BAD  Bcl-2-associated death promoter 
BCL-2  B-cell lymphoma 2 
Bcl-XL  B-cell lymphoma-extra large 
bFGF  basic fibroblast growth factor 
BH3  Bcl-2 homology domain 3 
BIM  Bcl-2-like protein 11 
CC3  cleaved caspase 3 
CCND  cyclinD1 gene 
CDK  cyclin dependent kinase 
CK  cytokeratin 
CK2  casein kinase 2 
cMyc  cellular myelocytomatosis oncogen 
CREB  cAMP response element-binding protein 
CSC  cancer stem cell 
CTGF  connective tissue growth factor 
DC  Dupuytren contracture 
DEN  diethylnitrosamine 
Deptor  DEP domain-containing mTOR-interacting protein 
DMSO  dimethyl sulfoxide 
DNA-DSB DNA double strand breaks 
DNA-PK DNA-dependent protein kinase 
ECM  extracellular matrix 
EGF  epidermal growth factor 
EGFP  enhanced green fluorescent protein 
ELISA  enzyme-linked immunosorbent assay 
EMT  epithelial-mesenchymal transition 
eNOS  endothelial nitric oxide synthase 
ERK  extracellular signal–regulated kinase 
EYFP  enhanced yellow fluorescent protein 
FasL  Fas ligand 
FOXO  Forkhead family subclass O 
FP  fluorescence polarization 
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INTRODUCTION 
Cells are exposed to several extracellular stimuli, like hormones, cytokines and 
growth factors, which induce intracellular signaling pathways that ultimately 
regulate cell proliferation, apoptosis, differentiation, metabolism and angio-
genesis. Strict balance between growth promoting and suppressing factors ensures 
the normal life cycle of the cell. With time the accumulating mutations and 
epigenetic changes can alter the signaling network, which drives the normal cell. 
Cancer may arise when normal cellular growth goes awry due to defects in 
critical signal transduction pathways. Most of the somatic mutations found in 
cancers, typically 40–90 per cell, are considered harmless. A smaller set of 
mutations occurring frequently in critical genes, like proto-oncogenes and tumor 
suppressors, are called “driver” mutations, which form the basis of oncogenesis. 
The identification of tumorigenic mutations and elucidating their impact on cell 
functioning has defined core signaling pathways that participate in multistep 
development of cancer. Protein-protein interactions (PPI) in these identified 
signaling cascades, which play crucial role in malignant transformation, are 
attractive targets for intervention with small molecular compounds. Despite of the 
challenges that the researchers face when designing the PPI inhibitors, the number 
of small molecules specifically interfering PPIs, which are crucial for the integrity 
of the pathway of interest, is constantly growing. 
In last decades it has become apparent that PI3K/AKT signaling pathway, 
which has a key role in normal physiological processes, such as cell cycle pro-
gression, differentiation, survival, transcription, translation, endocytosis, motility, 
metabolism and autophagy, is also one of the most frequently dysregulated 
pathways in human tumors. Aberrantly activated AKT pathway has been com-
monly described in prostate, breast, liver, and colorectal carcinomas. Recently, 
active AKT pathway has also been linked to cancer stem cells. Moreover, the 
constitutive activation of the PI3K/AKT pathway confers resistance to many 
chemotherapeutic drugs and is a poor prognostic marker for a number of cancer 
types. Due to AKT involvement in critical steps of human tumor pathogenesis, 
targeting AKT pathway has become a promising strategy in anti-cancer therapy. 
Although a number of small molecule AKT kinase inhibitors have been 
developed, severe side effects have prevented their use in clinical trials. 
The current thesis is focused on active AKT pathway in cancer cells and in 
Dupuytren contracture tissue. Screening, based on Renilla luciferase protein com-
plementation assay (PCA), identified a small molecule compound NSC156529, 
that efficiently suppressed the signal transduction in PI3K/AKT pathway by inter-
fering AKT1 and PDPK1 interaction. Since NSC156529 efficiently decreased the 
proliferation of different human cancer cells in vitro and the growth of prostate 
tumor xenografts in vivo, it could be a new promising compound for drug 
development to inhibit the growth of cancer cells with elevated AKT activity. We 
also found that the activated AKT signaling might play a role in the progression 
of benign hyperproliferative pathology – the Dupuytren’s contracture.  
12 
LITERATURE OVERVIEW 
1. AKT kinases – classification and structure 
Protein kinase B or AKT (PKB/AKT) is a serine/threonine kinase, which 
belongs to AGC group of protein kinases (named after PKA, PKG and PKC), 
that share structural homology within their catalytic domain and have a similar 
mechanism of activation [1]. AKT/PKB was first described by three inde-
pendent groups. Coffer et al. found that the catalytic domain of kinase has 65% 
homology with PKA and 75% homology with PKC, hence the name PKB. In 
addition, they demonstrated that PKB is a downstream effector of PI3K acti-
vation [2]. Jones et al. analyzed kinases in a similar way but named it RAC-PK 
(related to A and C protein kinases) [3]. Bellacosa et al. found PKB, or c-Akt, 
to be a cellular homologue of v-Akt, the gene product of AKT-8, an acute trans-
forming retrovirus which was isolated from a rodent T cell lymphoma [4-6]. In 
mammals AKT family comprises three highly homologous members known 
as PKBα (AKT1), PKBβ (AKT2), and PKBγ (AKT3). AKT isoforms are 
encoded by different genes on chromosomes 14q32, 19q13, and 1q44, respec-
tively, and their amino acid sequences share approximately 80% similarity [7]. 
Despite of a close homology, the three isoforms of AKT localize in distinct sub-
cellular compartments and have different functions in normal cell physiology 
and development [8, 9]. AKT1/PKBα, which is localized in the cytoplasm, is 
required for whole body normal growth and mammary morphogenesis [10, 11]. 
AKT2 colocalizes with the mitochondria and is involved in glucose metabolism, 
adipogenesis and β-cell function [12]. AKT3, which is mainly found in the 
nucleus and nuclear membrane, is essential for the attainment of normal brain 
size [13]. All three AKT isoforms are expressed in a tissue-dependent manner. 
AKT1 is expressed ubiquitously at high levels with exception of the kidney, 
spleen and liver [3, 14, 15]. AKT2 expression is elevated in insulin-sensitive 
tissues such as fat cells, skeletal muscle and liver [16-19]. AKT3 is relatively 
highly expressed in the brain and testis, with low levels in skeletal muscle and 
liver [20]. 
To assess the functions of individual AKT isoforms, the gene expression 
of each of the Akt was disrupted in the mouse germ line via homologous recom-
bination. Mice lacking individual Akt isoforms are mostly viable. In knockout 
mouse experiments Akt1–/– mice have placental hypotrophy, partial neonatal 
mortality and reduced animal size from the embryonic stages [11, 21, 22]. The 
exposure to genotoxic stress decreases lifespan of Akt1−/− mice [21]. Akt1 
deficiency has also been related to angiogenesis and tumor development [11]. 
Interestingly, Akt1−/− mutants did not have a diabetic phenotype; the mice had 
either normal glucose tolerance and insulin-stimulated disposal of blood glu-
cose, or an improved insulin sensitivity and enhanced energy consumption 
compared to wild type animals [11, 23, 24]. Akt2 –/– knockout mice have nor-
mal growth characteristics, but they have a mild to severe insulin resistance 
(impaired insulin action in skeletal muscle, fat and liver) [25, 26]. Akt3–/– mice 
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have a specific deficiency in postnatal development of the brain and 20–25% 
decrease in brain size, which is at least partially caused due to smaller and fewer 
cells [13, 27]. Akt1/Akt3 double knockout causes embryonic lethality at around 
embryonic days 11 and 12, with more severe developmental defects in the car-
diovascular and nervous systems, apoptosis was also increased in the devel-
oping brain of double mutant embryos [28]. This indicates that Akt1 may have 
more important role in developing embryo than Akt3. Akt1/Akt2 double-
knockout mice show severe growth deficiency and die shortly after birth. These 
mice display impaired skin development due to a proliferation defect, severe 
skeletal muscle atrophy because of a marked decrease in individual muscle cell 
size, and impaired bone development [29]. 
All AKT proteins have a similar conserved protein structure – an amino 
terminal pleckstrin homology (PH) domain, a central kinase domain and a 
carboxyl-terminal regulatory domain (Figure 1) [1].  
 
 
Figure 1. Schematic structure of human AKT1 protein. AKT1 protein (length 480 
amino acids) contains a pleckstrin homology domain (PH), helical region (Helix), 
kinase domain (Kinase) and a regulatory motif (Regulatory). The two phosphorylation 
sites essential for complete activation (Thr308 and Ser473) and other post-translational 
modifications of AKT1 are indicated in the diagram. The activation loop is 
encompassed by DFG and APE motifs. C: carboxyl-terminal; N: amino-terminal. 
 
AKT pleckstrin homology (PH) domain, which comprises approximately 100 
amino acids in the N-terminal region of the protein, consists of seven β-strands 
forming two antiparallel β-sheets capped by a C-terminal α-helix. The β1–β2, 
β3–β4, and β6–β7 loops form a positively charged pocket that can adapt the 
PI3K-generated phospholipids in a complementary fashion through specific 
hydrogen-bonding interactions. The residues Lys14, Arg25, Tyr38, Arg48, and 
Arg86 form the bottom of the binding pocket and specifically interact with the 
3- and 4-phophate groups of the phospholipids, while residues Thr21 and Arg23 
are situated at the wall of the binding pocket and bind to the 1-phosphate group 
[30]. AKT PH domain interacts with membrane lipids, such as phosphati-
dylinositol (3,4,5)-trisphosphate (PIP3), the product of phosphatidylinositol  
3-kinase (PI3-kinase, PI3K), and is believed to play significant role in re-
cognition by upstream kinases as well as membrane translocation. 
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The kinase domain is located in the central region of the AKT molecule and 
it shares high similarity with other AGC group members, such as PKA, PKC, 
p70S6K and p90RSK [31]. The phosphorylation of the conserved threonine 
residue in the activation segment, which is required for enzymatic activation, is 
located in the C-lobe of the kinase domain between the DFG and APE motifs in 
the activation loop [31, 32]. 
Approximately 40 amino acid long carboxyl-terminal regulatory domain of 
AKT contains hydrophobic motif F-X-X-F/Y-S/T-Y/F (where X is any amino 
acid), which is characteristic to the AGC protein kinase family [31]. Phos-
phorylation of the Ser or Thr residue in this hydrophobic motif is necessary for 
full activation for all AGC family kinases. In mammalian AKT isoforms this 
motif is identical (FPQFSY) and very important, because deletion of it com-
pletely abolishes the enzymatic activity of the kinase [33]. It has been found 
that rat PKBγ/AKT3 and the human PKBγ-1 splice variant do not possess this 
motif, suggesting that these variants are activated by mechanisms independent 
of phosphorylation of the Ser/Thr residues in the hydrophobic motif [34, 35]. 
 
 
2. AKT activation and modification 
2.1. AKT1 phosphorylation at Thr308 and Ser473 
Full activation of AKT protein is a multistep process in which several proteins 
have been identified and characterized [36]. Stimulation of cells with growth 
factors, such as platelet derived growth factor (PDGF), insulin, epidermal 
growth factor (EGF), basic fibroblast growth factor (bFGF), insulin-like growth 
factor I (IGF-I) and vascular endothelial growth factor (VEGF), leads to the 
recruitment of phosphoinositide 3-kinase (PI3K) to the plasma membrane where 
it phosphorylates phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2, PIP2) 
to generate phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P3, PIP3) 
[37]. The major mechanism by which PIP3 exerts its physiological effect, is the 
interaction with proteins possessing pleckstrin homology (PH) domain [38]. 
AKT interaction with PIP3 via PH domain leads to a conformational change so 
that PH domain folds back and the phosphorylation sites become available. 
AKT interaction with PIP3 and recruitment to the membrane brings it to the 
close proximity to another PH domain containing serine/threonine kinase called 
phosphoinositide-dependent kinase 1 (PDK1 or PDPK1), which phosphorylates 
AKT1 at the site Thr308 (Thr 309 and 305 in AKT2 and AKT3 respectively) in 
the activation loop of the kinase domain.  
PDPK1 is one of the most conserved protein kinases found in eukaryotes, 
which belongs to AGC kinase family [39]. PDPK1 human gene product is a 556 
amino acid long polypeptide. Folded as a globular protein, it constitutes of two 
domains: N-terminal serine–threonine kinase domain and a C-terminal PH 
domain [40]. The kinase domain can be subdivided in two lobes (a small  
N-terminal lobe and a large C-terminal lobe), which include two important 
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regulatory sites: the PIF-pocket (or PIF-binding pocket) and the activation loop 
(or T-loop). The phosphorylation of PDPK1 at Ser241 in T-loop is done in trans 
by another PDPK1 molecule and is essential for its kinase activity [41]. Another 
important structural element of the kinase domain is the αC-helix which con-
nects the PIF-pocket with the activation loop and the bound ATP [42]. PDPK1 
is mainly localized in the cytoplasm. Upon increased PI3K activity, PDPK1 
moves to PIP3-enriched plasma membrane regions, which has been linked to its 
ability to regulate cell migration [43]. In specific situations it translocates into 
the nucleus with the mechanism that involves the inhibition of its Nuclear 
Export Sequence [44, 45]. 
AGC kinases, such as AKT, p90RSK, p70S6K, SGK and some PKC iso-
forms, carry two phosphorylation sites required for the regulation of their 
activity, one localized in the activation loop within the kinase domain, the other 
in the hydrophobic motif [46]. PDPK1 phosphorylates AGC kinases on their 
activation loop by two different mechanisms. By the first mechanism PDPK1 
phosphorylates AKT at Thr308 in the activation loop, which is essential for its 
activation [40]. PDPK1 and AKT both bind to PIP3 or PIP2 produced by PI3K 
at the plasma membrane by their PH domain [40, 47], which co-localizes the 
two proteins at the plasma membrane. AKT binding to these phospholipids 
determines a conformational change that allows the phosphorylation of Thr308 
on the activation loop by PDPK1 [48]. By the second mechanism PDPK1 phos-
phorylates and activates other AGC kinases, such as p70S6K [49], SGK [50], 
p90RSK [51] and atypical PKC isoforms [52]. In this case, PDPK1 binds the 
phosphorylated hydrophobic motif (HM) of these AGC kinases through its PIF-
pocket, which leads to their phosphorylation on the activation loop and their full 
activation [53]. Moreover, PDPK1 is able to bind and activate in a kinase 
independent manner some proteins belonging to AGC kinase family, such as 
ROCK1 [54] and MRCKα [43], or proteins not belonging to this family, such as 
PLCγ1 [55] and β3 integrin [56, 57]. 
Since PDPK1 knock-out mice die during the embryonic development, this 
protein is considered to be strictly required for survival of all eukaryotes. The 
main role of PDPK1 is to be a signal transducer in signaling pathways activated 
by several growth factors and hormones. PDPK1 is involved in glucose metabo-
lism by promoting glucose storage [58], development [59], blood vessel for-
mation [60], and neuron differentiation [61]. Moreover, alterations of PDPK1 
functions have also a relevant role in pathology such as Alzheimer’s disease 
[62], diabetes [63] and cancer [64, 65]. 
For full activation, AKT needs to be phosphorylated at Ser473 in the hydro-
phobic motif (Ser474 and Ser472 in AKT2 and AKT3 respectively) [66]. Phos-
phorylation of Ser473 is believed to be the key step in the activation of AKT 
because it stabilizes the active conformation state [67]. Molecular identity of the 
kinase phosphorylating AKT at Ser473 (referred also as „PDK2“) has been 
under debate for many years. Proposed candidates include PDPK1 [68], 
integrin-linked kinase (ILK) [69], AKT itself [70], mitogen activated protein 
kinase activated protein kinase 2 (MAPKAPK2) [32], protein kinase C II 
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(PKCII) [71] and the members of the atypical PI 3-kinase related protein kinase 
(PIKK) family: DNA-dependent protein kinase (DNA-PK) [72] and ataxia tel-
angiectasia mutant (ATM) [73]. Currently it is accepted that the main candidate 
for this action is the mechanistic/mammalian target of rapamycin complex 2 
(mTORC2). 
mTOR is a serine/threonine kinase that mediates signals from nutrients, 
stress and growth factors and thereby participates in cell metabolism, prolifera-
tion, autophagy and migration regulation [74-76]. mTOR is a member of a family 
of protein kinases termed the PIKKs (phosphatidylinositol-3-kinase-related 
kinases) and functions as serine/threonine protein kinase. As the name implies, 
mTOR is a specific target of the natural compound rapamycin. mTOR interacts 
with several proteins and forms two complexes named mTOR complex 
1 (mTORC1) and mTOR complex 2 (mTORC2). The conserved components of 
mTORC2 are mTOR, Rictor (mAVO3), SIN1 and mLST8 (GβL). Other pro-
teins found to be associated with mTORC2, such as PRR5/Protor, PRR5L and 
DEPTOR. Rictor and mSIN1 stabilize each other and are believed to create the 
basis for mTORC2 complex [77, 78]. mLST8 is essential to mTORC2 stability 
and activity [79]. Deptor is the negative regulator of mTORC2 activity [80]. 
mTORC2 phosphorylates AKT at Thr450 of the turn motif (TM) and Ser473 
of the hydrophobic motif (HM) [66, 81]. Thr450 phosphorylation is a post-
translational modification and occurs upon recruitment of AKT to the mem-
brane via affinity of its PH domain to membrane lipids. Phosphorylation at 
Ser473 is induced by such stimuli as growth factors and hormones and it leads 
to increased activity of AKT. Ser473 phosphorylation may be related to sub-
strate specificity, since AKT phosphorylation by mTORC2 at Ser473 has influ-
ence on Forkhead subclass O family of transcription factors (FOXO1/2) phos-
phorylation, but not on other substrates like GSK3 (glycogen synthase kinase 3) 
and TSC2 (tuberous sclerosis complex 2) [79]. Phosphorylation at Ser473 has 
been shown to be elevated in a number of cancers, indicating that the regulation 
of AKT by mTORC2 could play a significant role in cancer progression. 
 
 
2.2. Alternative AKT modifications 
Although, current evidence suggests that phosphorylation at Thr308 and Ser473 
are required for full activation of AKT1 protein, there is information about other 
post-translational modifications, which influence AKT activity, subcellular 
localization, protein stability, protein folding etc. (Figure 1) [82]. 
Thr92 phosphorylation indicates to proper folding of AKT protein, whereas 
single mutation only marginally affects expression and activation of this kinase, 
but double mutation of Thr92 and Thr450 residues makes AKT unstable [83]. 
Ser124 high phosphorylation level has been detected in different cell lines [32]. 
According to one hypothesis phosphorylation of AKT at Ser124 renders the 
protein responsive to growth factor-induced and PI3K-dependent activation 
[84], but so far, there is no evidence of identified regulatory stimulus or kinase 
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involved with this event. Ser129 phosphorylation in vitro and in vivo by casein 
kinase (CK2) is associated with an increase in the catalytic activity of AKT, 
which is supported by the fact that down-regulation of CK2 catalytic subunit or 
a mutation of the CK2 target site in AKT correlates with decreased AKT 
activity [85]. Thr312 is believed to have an inhibitory effect on AKT acti-
vation. GSK3α phosphorylates AKT within the substrate-binding site of the 
protein and this modification is considered to interfere with the interaction of 
AKT and its substrates preventing AKT kinase function [86]. Since mutation of 
Thr450 only slightly inhibits the activation of AKT by growth factors [87], 
Thr450 is indicated as constitutively phosphorylated site, which controls AKT 
protein folding and maturation and has been proposed to be the first step in 
AKT activation [81, 88, 89]. In addition, constitutive phosphorylation of Thr450 
inhibits co-translational ubiquitination and subsequent degradation of AKT 
protein [89]. Very recently it was found that AKT activity fluctuation during the 
cell cycle is in correlation with cyclinA2 expression pattern. Further investi-
gation revealed cyclinA2 phosphorylation sites at the very end of the C-terminal 
domain of AKT protein – residues Ser477 and Thr479. Phosphorylation of 
these two residues is proposed to trigger AKT1 activation either through 
enhancing its association with mTORC2 to promote phosphorylation of Ser473 
or by functionally compensating the absence of pSer473 to lock Akt1 in its 
active conformation. In breast cancer samples as well as in breast-cancer-
derived cell lines they found a positive correlation between the phosphorylation 
of AKT1 at Ser477/Thr479 and Ser473. These results indicate that a physio-
logical role of cyclinA2 is to promote pro-survival and oncogenic properties of 
AKT1 protein [90]. Evolutionarily conserved Tyr176 can be directly phos-
phorylated by non-receptor tyrosine kinase ACK1 (also known as ACK or 
TNK2), which causes PIP3-independent recruitment of AKT to the plasma 
membrane and subsequent phosphorylation of Thr308/Ser473 leading to AKT 
activation. In addition, activated ACK1 expression in the prostate of transgenic 
mice specifically induces phosphorylation of AKT at Tyr176, which promotes 
the development of murine prostatic intraepithelial neoplasia (mPINs). Positive 
correlation between activated ACK1 and Tyr176 phosphorylation in breast 
tumor samples was also found to be related with poor prognosis of breast cancer 
patient survival [91]. Chen et al. found that AKT is a direct substrate of Src 
both in vitro and in vivo and that Tyr176 phosphorylation of AKT is critical for 
its full activation by growth factors. 
Two identified residues near the activation loop of AKT, Tyr315 and 
Tyr326, are found to be indispensable for AKT activation. Replacing these 
residues with phenylalanine blocked AKT kinase activity upon growth factor 
stimulation [92]. Non-myristylated Src-related intracellular tyrosine kinase pro-
tein tyrosine kinase 6 (PTK6) is also capable of phosphorylating AKT at 
Tyr315 and Tyr326 [93]. Conus et al. showed that AKT activation by per-
vanadate or serum is associated with Tyr474 phosphorylation on AKT. Tyr474 
substitution with phenylalanine abolished its phosphorylation and resulted in up 
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to 55% inhibition of AKT activation, indicating that phosphorylation at Tyr474 
is required for full activation of the kinase [94]. 
AKT inhibition. Among the many molecules that stimulate AKT are also 
these that inhibit AKT activity. Phosphatase and tensin homologue deleted 
chromosome 10 (PTEN) is a tumor suppressor, which has been frequently 
mutated in a variety of solid tumors [95]. This lipid phosphatase inhibits 
PI3K/AKT signaling indirectly by catalyzing the conversion of PIP3 into PIP2 
(Figure 2) [96]. PTEN is also involved in DNA-DSB repair following genotoxic 
stress such as exposure to ionizing radiation [97]. Protein phosphatases such as 
PHLPPs (PH-domain leucine-rich repeat protein phosphatases) and PP2A 
(protein phosphatase 2A) have a direct effect on AKT activity. PHLPP dephos-
phorylates Ser473 and thereby inactivates AKT proteins. Two PHLPP isoforms 
have distinct impact on AKT proteins: PHLPP2 dephosphorylates AKT1 and 
PHLPP1 dephosphorylates AKT2 and AKT3 [98]. Indicated as tumor sup-
pressor, PHLPP expression is commonly lost in human cancers [99]. PP2A 
preferentially dephosphorylates AKT at Thr308 [100]. 
 
 
3. AKT signaling pathway 
PI3K/AKT pathway is initiated by various growth factors, hormones and cyto-
kines, such as insulin, insulin like growth factor (IGF), epidermal growth factor 
(EGF), basic fibroblast growth factor (bFGF), vascular endothelial growth fac-
tor (VEGF) and platelet derived growth factor (PDGF). These factors bind to 
receptor tyrosine kinases (RTKs), cytokine receptors or GPCRs and trigger the 
activation of the lipid kinase PI3K. Activated PI3K phosphorylates PIP2 to pro-
duce PIP3, which recruits AKT to the cell membrane where it is phosphorylated 
at Thr308 and Ser473. Once activated, AKT migrates to the cytosol, mito-
chondria and nucleus, phosphorylates numerous substrates throughout the cell 
and thereby regulates multiple cellular events and processes like cell growth, 
survival, differentiation and metabolism (Figure 2) [101, 102]. 
Up to now, more than 100 proteins have been identified as potential AKT 
targets, including caspase-9, p27Kip1, p21Cip1/WAF1, glycogen synthase kinase 3 
(GSK3) cAMP response element-binding protein (CREB), murine double 
minute 2 (MDM2), BAD, proline-rich AKT substrate 40 (PRAS40), Forkhead 
family subclass O (FOXO) transcription factors etc. [54, 101, 102]. Most of the 
AKT substrates contain the minimal consensus sequence RxRxx(S/T), where x 
is any amino acid and S/T is the Ser/Thr phosphorylation site [103]. Many tar-
gets of the pathway modulated by AKT are also subjects for regulation by other 
pathways, further highlighting the extreme complexity of AKT signaling regu-
lation [104–106]. 
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Figure 2. Schematic representation of the PI3K/AKT pathway. Growth factor receptor 
activated PI3K phosphorylates PIP2 and produces PIP3, which recruits AKT to the cell 
membrane where it is phosphorylated by PDPK1 and mTORC2. Phosphorylated AKT 
regulates a plethora of downstream cellular processes from cell survival, angiogenesis, 
proliferation, translation and metabolism. AKT is dephosphorylated by PHLPP and PP2A. 
 
AKT signaling specificity. There is a large body of evidence about the diverse 
functions of AKT isoforms, but the mechanisms by which AKT isoform-
specificity is conferred are largely unknown. Selectivity might at least in part be 
reached through tissue-specific expression, spatial segregation at distinct 
subcellular locations and phosphorylation of isoform-specific substrates [103]. 
Since the subcellular localization of AKT isoforms in cancer cells is different 
[104], the current model of AKT activation by PI3K/PDPK1/mTORC2 might 
only be applicable to AKT1. 
 
 
3.1. AKT regulates cell survival and apoptosis 
AKT promotes cell survival by inhibiting the functions of pro-apoptotic pro-
teins and apoptosis related processes, or activates transcription factors, which 
regulate the expression of genes with anti-apoptotic activity (Figure 3). 
AKT inhibits the functions or expression of several Bcl-2 homology domain 
3 (BH3)-only proteins, which exert their proapoptotic effects by binding to and 
inactivating prosurvival Bcl-2 family members. AKT can directly phosphorylate 
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pro-apoptotic Bcl-2-antagonist of death (BAD), BAX and BIM [105-108]. 
Unphosphorylated BAD interacts with Bcl-XL, which leads to a release of 
cytochrome c from the mitochondrial compartment into the cytoplasm where it 
binds to Apaf1 thereby activating apoptotic proteases called caspases [109]. 
Phospho-serine residues Ser112 (phosphorylated by Raf1) and Ser136 (phos-
phorylated by AKT) on BAD form high-affinity binding sites for cytoplasmic 
14-3-3 molecules, which prevent BAD binding with BclXL [110, 111]. Ser112 
and Ser136 residues on BAD can also be phosphorylated by p21-activated 
kinase 1 (Pak) [112]. Pak activation is triggered by oncogenic Ras stimulation 
and subsequent AKT activation, which means that AKT can regulate BAD also 
indirectly [113].  
 
 
 
 
Figure 3. The substrates of AKT involved in blocking apoptosis and promoting cell 
survival. 
 
AKT regulates positively some transcription factors to allow expression of pro-
survival genes. Cell survival promoting cAMP response element binding 
protein (CREB) is phosphorylated by AKT at Ser133, which stimulates 
recruitment of CREB-binding protein (CBP) to the promoter of target genes, 
such as Bcl-2 [114]. AKT can phosphorylate and activate the IκB kinase IKKα 
at Thr23, causing degradation of IκB and nuclear translocation of NF-κB where 
it promotes expression of caspase inhibitors, c-Myb and Bcl-XL [115]. AKT 
also inhibits the expression of BH3-only proteins through effects on FOXO 
transcription factors [116]. AKT phosphorylates FOXO1 at Thr24, Ser256, 
Ser319 and FOXO3a and FOXO4 at three equivalent sites in the nucleus [117]. 
Phosphorylation of FOXO proteins by AKT triggers the rapid relocalization of 
FOXOs from the nucleus to the cytoplasm. Phosphorylated Thr24 and Ser256 
are binding sites for 14-3-3 proteins, which masks FOXO nuclear localization 
signal (NLS) and causes FOXO transcription factor translocation to the cyto-
plasm [118]. By this mechanism AKT blocks FOXO-mediated transcription of 
target genes that promote apoptosis, cell-cycle arrest, and metabolic processes, 
such as BIM [119] and proapoptotic cytokine Fas ligand (FasL) [120]. Down-
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stream of cytochrome c release AKT can phosphorylate caspase 9 at Ser196 in 
human cells, which leads to an inhibition of caspase activity through an 
unknown mechanism [121]. AKT can interact and phosphorylate X-linked 
inhibitor of apoptosis protein (XIAP) at residue Ser87 in vitro and in vivo. 
Phosphorylation of XIAP by AKT prevents XIAP ubiquitination and degra-
dation in response to cisplatin and also XIAP autoubiquitination [122]. By sta-
bilizing XIAP, AKT promotes cell survival.  
 
 
3.2. AKT regulates cell cycle progression and proliferation 
AKT kinase modulates the activity, localization and functions of several sub-
strates related to cell cycle progression at the G1/S and G2/M transitions, either 
by directly phosphorylating the target proteins or indirectly regulating their 
expression levels (Figure 4). Growth-factor-mediated AKT activation causes 
cells to exit G0 via directly increasing the transcription of proto-oncogene  
c-Myc (cellular myelocytomatosis oncogen), which executes its multiple activi-
ties mostly through transcriptional regulation of the target genes [123]. c-Myc 
induces the expression of D-type cyclins (cyclinD) and inhibits the expression 
of negative cell cycle regulators such as p21Cip1/WAF1, p27Kip1 and p15INK4b 
[124-126]. Indirectly AKT controls the stability of c-Myc and cyclinD1 via its 
downstream substrate GSK3β. c-Myc phosphorylation at Thr58 and cyclinD1 
phosphorylation at Thr286 by GSK3β is required for ubiquitin-dependent pro-
teolysis of these proteins [127, 128]. 
p21Cip1/WAF1 is a critical regulator of cell cycle progression and cell survival. 
p21Cip1/WAF1 inhibits the kinase activity of the cyclin-dependent kinases (CDKs), 
leading to cell growth arrest at specific stages in the cell cycle. p21Cip1/WAF1 
binding to proliferating cell nuclear antigen (PCNA) interferes PCNA-dependent 
DNA polymerase activity and thereby inhibits DNA replication and modulates 
various PCNA-dependent DNA repair processes [129]. Elevated p21Cip1/WAF1 
protein levels have been observed in various aggressive tumors and it has been 
linked to enhanced survival and chemoresistance [27]. p21Cip1/WAF1 is reported to 
be a direct substrate of AKT [130]. AKT phosphorylation of p21Cip1/WAF1 at 
Thr145 in the nuclear-localization signal (NLS) leads to the cytoplasmic 
localization and suppression of the inhibitory effect of p21Cip1/WAF1 on cell cycle 
progression [130]. In addition, AKT-dependent phosphorylation of p21Cip1/WAF1 
at Thr145 prevents the formation of DNA replication inhibiting complex 
between p21Cip1/WAF1 and PCNA, and decreases the binding of the cyclin-
dependent kinases CDK2 and CDK4 to p21Cip1/WAF1 [131]. Alternatively, it has 
been found that AKT phosphorylation of p21Cip1/WAF1 at Ser146 significantly 
increases p21Cip1/WAF1 protein stability and thereby modulates p21Cip1/WAF1 
protein level [132]. AKT induced p21Cip1/WAF1 protein can promote the assembly 
and activation of cyclinD1-CDK4 complex, which controls G1 to S phase pro-
gression and enhances cell cycling [132]. These data suggest that p21Cip1/WAF1 
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protein stabilization is an additional mechanism, by which AKT regulates tumor 
cell survival and/or proliferation. 
 
 
 
Figure 4. AKT role in cell cycle progression. Activated AKT kinase regulates the func-
tion of numerous proteins involved in cell cycle progression, either by direct phos-
phorylation of the target proteins or indirectly, by controlling protein expression levels.  
 
AKT controls the expression, localization, and protein stability of another major 
cyclin/CDK inhibitor - p27Kip1. AKT directly binds to and phosphorylates 
p27Kip1 at several residues, such as Ser10, Thr157, Thr187 and Thr198 [133-
137]. Thr157 phosphorylation within the nuclear localization sequence (NLS) 
leads to cytoplasmic accumulation of p27Kip1. In the cytoplasm p27Kip1 is not 
able to bind and inhibit nuclear cyclinE/CDK2 kinase activity and thus halting 
cell cycle progression. p27Kip1 phosphorylation by AKT at Thr198 promotes 14-
3-3 binding and cytoplasmic localization [138]. Cytoplasmic localization of 
p27Kip1 has been observed in various human tumors [139, 140]. In up to 40% of 
primary human breast cancers, cytoplasmic p27Kip1 correlates with AKT 
activation, indicating that AKT-mediated cytoplasmic mislocalization of p27Kip1 
may be critical in the development of human cancers. In addition, AKT can 
downregulate p27Kip1 transcription by phosphorylation-dependent inhibition of 
the FOXO transcription factors [141]. Protein stability of p27Kip1 is controlled 
by AKT-dependent phosphorylation of S-phase kinase-associated protein 2 
(Skp2) [142, 143]. Skp2 is a key component of SCF (Skp1/Cul-1/F-box) E3 
ubiquitin ligase, which binds to p27Kip1 and targets it for ubiquitination and 
degradation [144, 145].  
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The tumor suppressor p53 binds to DNA and up-regulates the expression of 
several genes involved in cell cycle control, DNA repair, senescence, angio-
genesis, and apoptosis [146-148]. In normal cells p53 is maintained at low 
levels by MDM2, which targets p53 for ubiquitination, translocation from the 
nucleus to the cytoplasm and proteolysis [149, 150]. By growth factor stimu-
lation activated AKT binds to and phosphorylates MDM2 at Ser166 and 
Ser186, which is necessary for the translocation of MDM2 from the cytoplasm 
to the nucleus, to enhance protein stability and facilitate the function of MDM2 
to promote p53 ubiquitination [151, 152]. MDMX, which is a MDM2 homo-
logue, has also been shown to be an AKT target. MDMX alone does not have 
E3 ubiquitin ligase activity, but it binds to and stabilizes MDM2 thereby pro-
moting p53 ubiquitination [153]. AKT phosphorylation of MDMX at Ser367 
generates a 14-3-3 binding site and leads to the stabilization of the MDM2-
MDMX complex [154]. Through MDM2 phosphorylation and activation AKT 
has impact also on transcriptional targets of p53, like BH3-only proteins PUMA 
(p53 upregulated modulator of apoptosis) and Noxa, which appear to be essen-
tial for p53-induced apoptosis [155]. 
AKT regulates the phosphorylation of cyclin-dependent kinase 2 (CDK2), 
which is a key regulator of G1-S cell cycle progression [156]. AKT phosphory-
lation of CDK2 at Thr39 in the nucleus causes temporary localization of 
cyclinA/CDK2 complex into the cytoplasm, which is required for cell cycle 
progression from S to G2/M phase [157]. Alternatively, AKT-mediated phos-
phorylation and cytoplasmic translocation of CDK2 is also important for stress 
induced apoptosis [158]. Phosphatase Cdc25B has an essential role in control of 
cyclinB/CDK1 activity [159] The function of Cdc25B is tightly linked to its 
intracellular localization [160, 161]. AKT-mediated Ser353 phosphorylation 
causes the cytoplasmic accumulation and inactivation of Cdc25B by avoiding 
the access to its substrates [162]. WeeHu, a CDK1 inhibitor, is also an AKT 
target. AKT phosphorylates WeeHu at Ser642, which does not affect its kinase 
activity, however, it promotes the interaction of WeeHu with 14-3-3 protein and 
translocation into the cytoplasm [163]. 
 
 
3.3. AKT regulates cell growth and metabolism 
In response to growth factors, AKT also regulates nutrient uptake and cell 
metabolism. One of the most important physiological functions of AKT is to 
regulate the glucose uptake in response to insulin. AKT activity increases the 
transcription of the glucose transporters GLUT1 and the translocation of 
GLUT4 to the plasma membrane in muscle and fat cells, which increases the 
uptake of glucose into cells [164, 165]. Other AKT substrates that may regulate 
cell metabolism by mediating the regulation of GLUT4 translocation include 
AKT substrate of 160 kDa (AS160), phosphoinositide kinase for five position 
containing a Fyve finger (PIKfyve) and syntaxin binding protein 4 
(STXBP4/synip) [166-168]. After entering into the cell, glucose is converted 
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by hexokinase to glucose-6-phosphate. AKT stimulates the association of hexo-
kinase with mitochondria, where it can access its glucose substrate more 
readily, but the direct target of AKT is currently unknown [169, 170]. Next, 
glucose 6-phosphate is stored by conversion to glycogen or catabolized to pro-
duce cellular energy through glycolysis. AKT regulates glycogen synthesis and 
suppression of glycogenolysis through the AKT-dependent phosphorylation and 
inactivation of GSK3. Nonphosphorylated GSK3 is catalytically active and 
inhibits the activity of glycogen synthase [171]. Activated AKT phosphorylates 
and inhibits GSK3 and prevents GSK3 from phosphorylating and inhibiting 
glycogen synthase, thereby stimulating glycogen synthesis. AKT can regulate 
glucose homeostasis also by phosphorylation and inhibition of FOXO1, as 
FOXO1 promotes hepatic glucose production and regulates the differentiation 
of cells involved in metabolic control [172]. In hepatocytes, AKT can inhibit 
gluconeogenesis and fatty acid oxidation through direct phosphorylation of 
peroxisome proliferator-activated receptor γ (PPARγ) coactivator 1 α (PGC-1α) 
at Ser570, which is a coactivator that can regulate genes with FOXO1 and other 
transcription factors [173]. AKT activation also increases the rate of glycolysis, 
which is common event seen in tumor cells [174]. AKT ability to enhance the 
rate of glycolysis is at least partly related to its ability to promote the expression 
of glycolytic enzymes through hypoxia-inducible factor 1-alpha (HIF1α) [175, 
176]. AKT-dependent phosphorylation and inhibition of GSK3 also regulates 
lipid metabolism. Phosphorylation of substrates by GSK3 often targets them for 
proteasomal degradation. GSK3 has been shown to promote degradation of the 
sterol regulatory element-binding proteins (SREBPs), which are transcription 
factors that turn on the expression of genes involved in cholesterol and fatty 
acid biosynthesis. AKT-mediated inhibition of GSK3 promotes SREBP stability 
and enhances lipid production [177]. AKT can also phosphorylate Ser454 on 
ATP citrate lyase (ACL), indicating a potential role in regulating ACL activity 
and fatty acid synthesis [178]. In addition, AKT activates the 3B isoform of 
cyclic nucleotide phosphodiesterase (PDE) via phosphorylation at Ser273, 
resulting in reduced cyclic-AMP levels and inhibition of lipolysis [179]. 
Promoting the cell growth (including an increase in cell mass) is one of the 
conserved functions of AKT. The predominant mechanism of AKT-dependent 
cell growth involves mTORC1 (mTOR complex 1 or the mTOR-raptor 
complex), which is activated by nutrients or growth factors. mTORC1 has a 
critical role in cell growth control, translation initiation and ribosome biogenesis 
[180]. mTORC1 is composed of mTOR, raptor (regulatory associated protein of 
mTOR), mLST8 (also called G-protein-subunit-like protein, GL), PRAS40 and 
deptor (death domain containing mTOR interacting protein) (Figure 5) [181]. 
mTORC1 regulates translation by phosphorylating its various downstream 
effectors from which the best characterized are p70 ribosomal protein S6 kinase 
1 (p70S6K1) and eukaryotic translation initiation factor 4E-binding protein 
1 (EIF4E-BP1). Ras homolog enriched in brain (Rheb) GTPase directly binds to 
the catalytic domain of mTOR and acts as a positive regulator of mTORC1 
kinase activity [182]. TSC1 and TSC2 proteins form in vivo a complex, which 
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negatively regulates mTORC1 by acting as Rheb GAP (GTPase activation pro-
tein) that converts Rheb into an inactive GDP bound form [183]. In response to 
growth factors, AKT directly phosphorylates TSC2 on several distinct residues 
(Ser939 and Thr1462), which prevents the formation of TSC1-TSC2 complex, 
thus allowing GTPase Rheb to convert back into the GTP-bound active state 
leading to mTORC1 activation (Figure 5) [184].  
 
 
 
 
Figure 5. PI3K–AKT signaling activates mTOR complex 1 (mTORC1) through the 
phosphorylation of TSC2 at position Ser1462. This phosphorylation event results in the 
dissociation of the TSC1–TSC2 complex and thus prevents TSC2 from stimulating the 
intrinsic GTPase activity of the small G protein RHEB, resulting in the accumulation of 
GTP-bound RHEB, which is a positive regulator of mTORC1. AKT also phosphory-
lates 40 kDa proline-rich AKT1 substrate PRAS40 at position Thr246, resulting in its 
dissociation from mTOR and thus blocking PRAS40-mediated mTORC1 inhibition. 
mTOR complex 2 (mTORC2) phosphorylates AKT at Ser473 and Thr450. 
 
Thus PI3K/AKT signaling pathway regulates mTORC1 by phosphorylation and 
inhibition of TSC2 which impairs its ability to inhibit Rheb, thereby resulting in 
the subsequent activation of Rheb and mTORC1. AKT activation by growth 
factors can stimulate mTORC1 also in a TSC1/2-independent manner through 
proline-rich AKT substrate 40 kDa (PRAS40). Unphosphorylated PRAS40 
binds raptor and inhibits mTOR kinase activity. PRAS40 phosphorylation by 
AKT at Thr246 promotes the dissociation of PRAS40 from mTORC1 and 
subsequent mTORC1 activation [182, 185]. 
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3.4. AKT regulates angiogenesis 
Angiogenesis is essential in many normal physiological processes, including 
embryogenesis, wound healing, tissue repair and organ regeneration, but it also 
contributes to several pathological conditions, like rheumatoid arthritis, tumor 
progression and metastasis. AKT participates in both physiological and patho-
logical angiogenesis through promoting angiogenic signal production and 
regulating the response of endothelial cells to these stimuli. Under physiological 
conditions, angiogenesis is tightly regulated through a local balance between 
angiogenic stimulators, such as growth factors VEGF, bFGF, TGFβ and PDGF, 
and angiogenic inhibitors like thrombospondin-1 (TSP-1), tissue inhibitor of 
matrix metalloproteinase-1 (MMP-1), angiostatin and endostatin. The formation 
of new blood vessels in pathological disorders is often due to either a decrease 
in levels of inhibitors, an increase in levels of stimulators or a combination of 
both [186]. 
In endothelial cells PI3K/AKT pathway is activated by vascular endothelial 
growth factor (VEGF), which thereby promotes the survival, growth and pro-
liferation of these cells [187]. One of the major stimuli for increased VEGF 
production by tumor cells is hypoxia, which is characteristic to advanced solid 
tumors. Hypoxia leads to the induction of hypoxia-inducible factor 1 (HIF-1) 
[188]. HIF-1 is a heterodimeric transcriptional factor, which is composed of 
HIF-1α and HIF-1ß subunits. Under hypoxic conditions the ubiquitin-mediated 
degradation of HIF-1α is inhibited and stabilized α subunit binds to the β subu-
nit, which is constitutively present. Composed heterodimer binds to numerous 
promoters containing hypoxia response elements (HREs), leading to the 
transcription of multiple target genes including VEGF [189]. In addition, HIF-
1α production and VEGF expression can be increased by the activation of 
EGFR/PI3K/AKT/mTOR pathway and PTEN mutation [190]. HIF-1α acti-
vation in endothelial and other surrounding cells leads to elevated expression 
and secretion of VEGF, which therefore stimulates angiogenesis through 
autocrine and paracrine manner. 
AKT regulates angiogenesis through the activation of endothelial nitric oxide 
synthase (eNOS), which catalyzes nitric oxide (NO) synthesis in endothelial cells. 
AKT phosphorylates eNOS at Ser1177, by leading to a persistent, calcium-
independent eNOS activation [191]. The activity of eNOS is also regulated by 
subcellular localization and protein-protein interactions. eNOS can be localized in 
a specific domain of plasma membrane called caveolae, where it interacts with 
caveolin-1 through caveolin-1 scaffolding domain, which inhibits eNOS activity. 
Stimulation with VEGF or stress induces eNOS to interact with heat shock 
protein 90 (Hsp90), and this interaction enhances eNOS activity. Remarkably, 
on stimulation, AKT can also interact with Hsp90 and this interaction enhances 
AKT enzymatic activity, which suggests that Hsp90 may serve as a scaffold 
protein for the efficient phosphorylation of eNOS by AKT at caveolae [192]. 
Elevated levels of VEGF and subsequent eNOS activity can lead to vascular 
permeability, leaky vessels, slow blood flow, and elevated interstitial pressure. 
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Constitutive activation of the ERK/MAPK pathway could induce angiogenesis 
but not vascular permeability, while activation of PI3K/AKT was required for 
both angiogenesis and vascular permeability [193]. In animal studies over-
expression of constitutively active AKT in the vascular endothelium increased 
resting diameter and blood flow, whereas transduction of dominant-negative 
AKT attenuated endothelium-dependent vasodilation induced by acetylcholine, 
suggesting that AKT regulates the vasomotor tone in vivo [194]. 
 
 
4. AKT and cancer 
4.1. AKT signaling in cancer 
Since AKT kinases control essential cellular processes, it is inevitable that the 
dysregulation of AKT signaling pathway leads to the loss of the strict balance 
between AKT-regulated tumor suppressor factor activities and proto-oncogenes, 
which yields severe consequences. Less active or defective AKT-dependent 
pathway does not provide an efficient protection from apoptotic signals, which 
may contribute to the pathogenesis and/or progression of several human 
disorders, such as type-2 diabetes, neurodegenerative diseases or illnesses of the 
cardiovascular system [195-200]. The overexpression and/or constitutively 
increased activity of the AKT-regulated pathway has been observed in a wide 
variety of human cancers, including carcinomas, glioblastoma multiforme and 
various hematological malignancies [201, 202]. Elevated AKT activity is 
usually not a result of any single event, but rather a consequence of multiple 
causes, which lead to AKT-dependent suppression of apoptosis, differentiation 
and to uncontrolled cell cycle progression. The AKT activity may be caused of 
increased amounts of extracellular factors that stimulate AKT signaling, altered 
number of receptors, which mediate these signals, constitutively activating 
mutations in these receptors as well as deregulation of intracellular AKT-
activating mediators, like Ras or PI3K and their regulators [203]. The control 
mechanisms that regulate AKT activity can be downregulated or deleted; for 
example, tumor suppressor protein PTEN has been found mutated or deleted in 
many advanced cancers [204, 205]. The elevated expression of AKT isoforms 
has been described in some cancer types, like pancreatic, prostate and mammary 
cancer [20, 206-208]. Amplification of AKT1 is rather rare, but amplification of 
AKT2, found in several cancer types, is more common [206, 209, 210]. AKT3 
amplification has recently been reported to promote DNA repair and glioma 
progression [211]. Carpten et al. described a transforming point-mutation E17K 
(lysine substituted with glutamic acid at position 17) within the PH domain of 
AKT1 in human breast, ovarian and colorectal cancer, which increases the 
plasma membrane recruitment and confers to the constitutively active state of 
the protein [212]. Analogous point-mutation in the AKT3 has been found in 
human melanoma [213]. AKT hyperactivation has frequently been found in less 
differentiated tumors, which are more invasive, grow faster and do not respond 
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to treatment. In addition, hyperactivated AKT in primary tumors is considered 
as poor prognostic marker for disease outcome [214].  
Considering the central role in cell signaling and frequent aberrant regulation 
in human cancers, AKT has become an attractive target in anti-cancer drug 
design. A better understanding of upstream regulators and downstream targets is 
necessary to control and regulate activity of AKT-related pathway in human 
malignancies. However, it has to be remembered that AKT signaling pathway is 
not only multifaceted and complicated but it is a part of a more complex and 
integrated network. To date, direct or indirect communication of AKT pathway 
with RAF-MEK1/2-ERK1/2, NFkB, JNK, p38, Wnt, p53 and NOTCH path-
ways has been described, which means that activation or inhibition of one of 
these pathways may have a strong impact on other signaling pathways as well 
[152, 215-219]. 
 
 
4.2. AKT and cancer stem cells 
Since PI3K/AKT/mTOR pathway is implicated in resistance mechanisms to 
antineoplastic therapies, it is rapidly emerging as a signaling network important 
for cancer stem cell (CSC) survival. CSC have suggested to be immortal tumor-
initiating cells that have self-renewal and pluripotent capacity [220]. CSCs have 
been identified in multiple malignancies, including leukemia and various solid 
cancers, such as lung cancer, colon cancer, prostate cancer, ovarian cancer, 
brain cancer and melanoma. CSCs are thought to be responsible for tumor ini-
tiation, development, metastasis and recurrence, and to be resistant to conven-
tional anti-tumor treatment, like polychemotherapy, which only acts on more 
mature cells. The reason could be the different regulation of gene expression 
and some signaling pathways compared to other tumor cells, like the elevated 
expression of ATP-binding cassette (ABC) family membrane transporters [221], 
or the fact that CSCs have low proliferation rate [222, 223]. Cell surface 
proteins CD133, CD24 and CD44 are considered as putative markers for cancer 
stem cell populations, associated with aggressive cancer types and poor 
prognosis. However, distribution of these markers differs between patients and 
cell lines [224]. In contrast, tumor initiating cells from head-and-neck and 
breast cancer have been shown to be CD24-negative [225].  
Probably due to different experimental models and methods, the published 
findings regarding the role of AKT in promoting cancer stem-cells are contro-
versial. AKT co-expression with CD133 has been shown to provide the cells 
resistance to chemotherapeutics [226]. Whereas AKT activation has been found 
both negatively as well as positively correlated with CD44 expression [227, 
228]. Radiation itself can increase the expression of AKT, CD133, and reduce 
the expression of CD44 in colorectal cancer cells [229]. The study with colon 
cancer cell lines showed that cells highly expressing CD133/CD44 have ele-
vated expression of AKT and these cells are more resistant to radiation. In 
addition, AKT isoforms had different influence on CD44 and CD133 expres-
29 
sion. Knocking down AKT1 but not AKT2 in colon cancer cell line, reduced 
CD133 expression. CD44 expression was increased in both knockdown variants 
[230]. Gargini et al. demonstrated a close relationship between maintenance of 
the CSC-like phenotype and the survival of tumor initiating cells [231]. Inhibi-
ting PI3K activity or AKT1 activity was not only related to increased apoptosis 
but also reduced significantly stem cell/mesenchymal phenotype and recovery 
of epithelial-like markers. They also revealed that maintenance of stem cell-like 
phenotype and survival of these cells is linked to AKT-FOXO-Bim pathway 
[231]. Studies with hair follicle stem cells (HF-SCs) showed that the expression 
of permanently active form of AKT leads to HF-SC activation and increases the 
response to proliferative stimuli, at the same time maintaining their stem-cell 
identity and functionality. In addition, active AKT signaling increased tumor 
development and malignancy [232]. Recently it was found that cells over-
expressing Twist, a key transcriptional factor of epithelial mesenchymal 
transition (EMT), had cancer stem cell-like properties, such as tumorsphere 
formation and significantly elevated expression of ALDH1 (aldehyde 
dehydrogenase 1) and CD44. In addition, activation of β-catenin and AKT 
pathways correlated with the expression of CD44 in these cells and knockdown 
of β-catenin expression and inhibition of the AKT pathway substantially 
suppressed the expression of CD44 [233]. Recent study claims that the EMT 
and stem cell renewal programs are influenced by imbalance between AKT1 
and AKT2, which dysregulates the microRNAs that control these processes, 
rather than overall activity of AKT [234]. It has been noted that inactivation or 
deletion of tumor suppressor PTEN, the negative regulator of PI3K/AKT/mTOR 
signaling cascade, is important in conferring CSC properties in several types of 
solid tumors, like glioblastoma, hepatocellular carcinoma, prostate carcinoma, 
lung adenocarcinoma and breast carcinoma [235-240]. In glioblastomas, AKT 
activation correlated with stemness, invasivity, and increased tumorigenicity, 
whereas ERK activation correlated with tumor cell proliferation [241]. PTEN 
gene down-regulation was also detected when leukemic stem cells (LSCs) from 
chronic myelogenous leukemia (CML) patients were analyzed and compared 
with healthy hematopoietic stem cells (HSCs) [242].  
Although the present information about AKT kinase relationship with CSCs 
is controversial and needs further research, it is still obvious that AKT signaling 
can have an important role in preserving CSC characteristics, like tumor initia-
tion, self-renewal and pluripotency.  
 
 
5. Protein-protein interaction inhibitors 
Protein-protein interactions (PPI) have a central role in cellular biological 
processes, like extracellular signaling, protein translation, DNA-synthesis, pro-
tein degradation, programmed cell death etc. There are roughly 30 000 protein 
sequences in human genome, an estimated number of PPIs in human body 
reaches up to ≈400 000, and therefore PPIs are a large and important class of 
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highly promising targets for human therapeutics [243]. In cancer cells, PPIs are 
responsible for transmitting signals along molecular networks, by promoting 
tumorigenesis, invasion and metastasis. Large number of PPIs have a role in 
signaling networks that allow the acquisition and maintenance of cancer hall-
marks. PPIs promote oncogenic signals by cell proliferation stimulation, for 
example by aberrantly activated epidermal growth factor receptor (EGFR) and 
its downstream target Ras protein [244]. Cell survival signaling is activated by 
proteins like insulin-like growth factor 1 (IGF-1) and PI3K, which enables cells 
to resist apoptosis through several different ways. Transcription-dependent 
mechanism uses AKT-FOXO3a-14-3-3 axis and transcription-independent 
antiapoptotic mechanism AKT-BAD-14-3-3 pathway [105, 116]. In addition, by 
regulating mTOR complex, AKT promotes translation of growth promoting 
genes, like c-Myc [245]. Disruption of PPIs, which are critical for cancer 
progression and that cancer cells rely on for survival, offers a potential effec-
tive, although challenging strategy for development of anticancer treatment. The 
challenges to discover compounds that could inhibit PPIs are for example the 
lack of good starting points for drug design and the difficulty to distinguish the 
real interaction from false/artefactual binding. The concerning properties of 
PPIs include large PPI interface areas, lack of deep pockets, where small mole-
cule can dock, lack of noncontiguous binding sites and general lack of natural 
ligands. Protein-protein complexes are typically hydrophobic and have different 
amino acid residue composition than small-molecule binding sites [246]. The 
presence of hot spots (small subsets of amino acid residues that contribute the 
most of the free binding energy), post-translational modifications and natural 
ligands simplifies defining of targeting suitable interfaces.  
Current approaches to design PPI modulators include structure based design 
and different small-molecule screening methods [246]. Structural analysis helps 
to identify specific amino acid or peptide fragments, which are critical for pro-
tein-protein interactions. These methods include computational design of pep-
tides and peptide engineering [247], design of small molecules based on α-helix 
and β-sheet scaffolds [248], protein design strategies to stabilize α-helical motif 
[249]. Small-molecule screening allows the identification of PPI modulators 
when structural information is lacking or limited. Most widely used high 
throughput screening techniques in such cases include fluorescence energy 
transfer (FRET) and fluorescence polarization (FP) method [250], ELISA, flow 
cytometry, surface plasma resonance, label free methods [251], cell-based 
reporter assays, which are also able to identify cell-permeable compounds [252] 
and fragment based screening [253]. The screening method and structure based 
approach used in combination helps to find modulators with better pharmaco-
logical and physicochemical properties. 
Natural compounds like taxanes for tubulin and rapamycin for mTOR, which 
were discovered in the late 90s as potent stabilizers of PPIs, show the potential 
of PPI modulation as therapeutic target. Despite of challenges in PPI modulator 
design, more than 15 years after the mentioned discoveries novel small 
molecules targeting specific PPIs have entered clinical trials, and in some cases 
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already resulted in new therapeutics or optimized treatments. Probably one of 
the most studied PPI in cell-cycle pathway is MDM2-p53 interaction. MDM2 
interacts with a hydrophobic surface groove with three key hydrophobic 
residues Phe19, Trp23 and Leu26 on p53. These residues make up the “hot 
spot” which was targeted to identify molecules that can interrupt this specific 
interaction [254]. For now, seven MDM2-p53 inhibitors have progressed to 
clinical trials with promising results [243]. The inhibitors of apoptosis proteins 
(IAPs) are overexpressed or constitutively activated in tumor cells, resulting in 
evasion of programmed cell death. The XIAP (X-linked IAP) is the most potent 
caspase inhibitor among the IAP protein family, with the natural inhibitor 
SMAC [255]. After discovery of the SMAC protein in 2000, a number of 
SMAC mimetics have been designed, from which seven have reached clinical 
trials and five molecules are in clinical development [256]. The antiapoptotic 
Bcl2 members of the protein family, which protect the cells against apoptosis, 
by inhibiting the actions of the proapoptotic members, are in some cancer types 
overexpressed. Bcl-2 specific inhibitor ABT-199 (RG7601) is in phase 1 trials 
for chronic lymphocytic lymphoma or small lymphocytic lymphoma. Another 
Bcl2 inhibitor Obatoclax (GX015-070) is currently assessed in multiple phase 2 
clinical trials offers the opportunity to treat many forms of cancer both as a 
single agent and in combination with current treatments [243]. The inhibition of 
Hsp90 chaperone protein, which regulates the activity and stability of numerous 
targets, is able to shut down multiple oncogenic pathways [257]. Hsp90 
inhibitors not only elicit potent anti-cancer effects, but also render tumor cells 
susceptible to chemotherapy and/or radiation therapy [258]. 
Novel small molecules targeting PPIs, which have entered to clinical trials 
and already resulted in optimized treatments or new therapeutics, clearly 
demonstrate the potential of PPIs in drug development. 
 
 
6. AKT inhibitors 
Although AKT has been targeted by several small-molecule inhibitors, the 
development of an AKT-specific inhibitor is challenging due to its high 
sequence and structural homology to other kinases and proteins containing PH 
domains. Despite of that, a plethora of AKT inhibitors is under pre-clinical and 
clinical trials. 
AKT inhibitors can be divided into six major classes based on their mecha-
nisms of action [259]. The first class contains ATP competitive inhibitors, 
which bind to enzyme active site and display ATP-competitive behavior, like 
AKT2 inhibitor CCT128930 [260], AKT1 inhibitor GDC-0068 [261], which 
has entered to Phase II trials, the pan-AKT kinase inhibitors such as 
GSK2110183 (afuresertib) [262], which has entered Phase II trials, and AT7867 
[263], which is still in pre-clinical phase. The second class contains phospho-
lipid-like molecules, which prevent the generation of PIP3 by PI3K, thereby 
avoiding AKT translocation to the cell membrane and its subsequent activation. 
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This mechanism is utilized by phosphatidylinositol analogs such as Calbiochem 
AKT Inhibitors I, II and III (category no. 124005, 124008, 124009 respectively) 
[264] or other PI3K inhibitors such as PX-866 [265]. This category also 
includes compounds such as Perifosine that entered phase III trials for colorec-
tal cancer and multiple myeloma, but failed in 2012 [266]. The third class con-
tains a group of compounds called pseudosubstrate and substrate-mimetic inhib-
itors, which include compounds like AKTide-2 T and FOXO3 hybrid [267]. 
These peptides are potent selective inhibitors of AKT, that bind to substrate 
binding site and inhibit AKT1 enzyme activity. Unfortunately, their size makes 
them poor leads for small molecule inhibitor development. The fourth class 
consists of allosteric inhibitors of AKT kinase domain, like MK-2206. MK-
2206 is an orally bioavailable allosteric inhibitor of AKT, which binds to and 
inhibits the activity of AKT in a non-ATP competitive manner by inducing a 
conformational change of AKT to the closed cytoplasmic conformation [268]. 
MK-2206 is currently widely examined in several clinical trials in phase II 
status in combination with other targeted drugs and chemotherapy. The fifth 
class consists of antibodies and include entities such as GST-anti-AKT1-MTS 
[269]. The last class comprises of compounds that interact with the PH domain 
of AKT, and include compounds such as Triciribine and PX-316 [270]. 
Triciribine is a cell-permeable tricyclic nucleoside that inhibits the 
phosphorylation, activation, and signaling of all three family members of AKT 
[271]. RX-0201 (Archexin) is an antisense oligonucleotide directed toward 
AKT1 mRNA, which significantly downregulated the expression of AKT1 at 
both mRNA and protein level [272].  
Although, various drug trials have been initiated for AKT inhibitors, only 
miltefosine has been recently approved by FDA for treatment of leishmaniasis, 
which is a disease caused by an intracellular protozoan parasite (genus 
Leishmania) transmitted by the bite of a female phlebotomine sandfly.  
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RESULTS 
Objectives of the study 
The main objectives of present work were as follows: 
• to identify AKT pathway inhibitors with principally novel mechanism of 
action, by targeting the crucial step in the AKT pathway – the interaction of 
PDPK1 and AKT1 proteins, which leads to AKT phosphorylation and 
subsequent activation of AKT-related pathways (REF I). 
• to use DEN-phenobarbital induced mouse liver tumor tissue derived primary 
mouse liver tumor cell line K07074 as a model system for testing the effect 
of chemotherapeutic agents that could target the pathways deregulated in 
liver tumors (REF II). 
• to study the specific areas in Dupuytren´s contracture (DC), which sustain 
active cell proliferation, to describe the potential molecular factors that could 
promote the DC pathogenesis (REF III). 
 
 
1. A Novel Inhibitor of AKT1–PDPK1 Interaction Efficiently 
Suppresses the Activity of AKT Pathway and  
Restricts Tumor Growth In Vivo (REF I) 
Ser/Thr kinase AKT has a central role in regulating survival and proliferation of 
normal and cancerous cells [201, 273]. Since inadequately regulated AKT path-
way has been found in several human malignancies [274], it has become an 
attractive target for treatment of different types of cancer. Although a number of 
small molecule AKT kinase inhibitors have been developed, only a few are 
suitable for clinical trials due to severe side effects, which have prevented their 
further use. To find inhibitors of AKT1 signaling with principally novel mecha-
nism of action, we carried out a live cell-based screen for small molecule inhibi-
tors of physical interaction between AKT1 and its primary activator PDPK1.  
 
 
1.1. Screening for the inhibitors of AKT1 and PDPK1 interaction 
Small-chemical library screen was carried out in live cells by using the NCI 
Diversity Set I. The screening method, protein complementation assay (PCA), is 
based on Renilla reniformis luciferase (Rluc) fragments (F1 and F2) that are 
fused to the proteins of interest [275]. When the proteins of interest interact, the 
Renilla fragments are brought in close proximity, which results in reconstitution 
of the enzyme activity (Figure 1 in REF I), and vice versa, the inhibition of 
protein-protein interaction unfolds the functional enzyme and destroys the Rluc 
activity. To assess the quality of the screen setup, Z-factor was measured using 
the constructs encoding p53-F1 and HDM2-F2 fusion proteins and the inhibitor 
of p53-HDM2 interaction – Nutlin-3. The value of the Z-factor for this assay 
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was 0.5, demonstrating its suitability for detecting the inhibition of the protein-
protein interactions.  
For screening experiments, H1299 cells, which harbor an active AKT sig-
naling pathway and are well-suited for DNA transfection experiments, were 
used [276] (Figure 1B in REF I). To exclude unspecific readouts of luciferase 
modulation, a number of controls were included in the screen setup (Table S4 
in REF I). Well-to-well variations were eliminated by normalizing the lucif-
erase read values to cell viability counts. The viability counts were also used to 
identify and exclude toxic compounds. Baseline values were set according to 
DMSO (vehicle) treated cells. As controls, each experiment assay included cells 
that were transfected with p53-F1 and HDM2-F2 fusions and treated with 
Nutlin-3 or vehicle. At least 2-fold reduction in luciferase activity upon Nutlin-
3 addition was considered as successful experiment. To eliminate the chemicals, 
which directly inhibited the Rluc activity, cells transfected with plasmids 
encoding full-length Rluc were treated with the chemical library in parallel. 
Taken together the selection criteria for compounds were set as follows: 1) at 
least 2-fold reduction of normalized Rluc activity representing the disruption of 
AKT1-PDPK1 interaction; 2) 25% or less reduction in cell viability counts 
when compared to the average of untreated controls; 3) less than 10% reduction 
in the normalized luciferase signal in cells transfected with full-length Rluc 
when compared to the average reading of untreated cells (Figure 1C in REF I).  
The screen was performed in two major steps. First, 74 chemicals out of 
2,000 were identified, as inhibitors of AKT1-F1–PDPK1-F2 interaction that 
reduced the luciferase signal at least to 50% or less. In the second step, the 
selected 74 chemicals were retested for AKT1–PDPK1 PCA inhibition and the 
inhibition of full-length Rluc and cell toxicity were evaluated. From 74 chemi-
cals that inhibited the AKT1–PDPK1 PCA, 29 chemicals also inhibited the 
activity of full-length Rluc, and 13 chemicals were toxic for cells. Nine more 
chemicals from remaining 45 were excluded from further analysis due to 
toxicity as these reduced the viability counts more than 25%. Consequently, 36 
chemicals were selected for the next evaluation step. 
 
 
1.2. NSC156529 reduces AKT phosphorylation level and  
inhibits AKT1-PDPK1 endogenous interaction 
Since the hallmark of AKT1 activation by PDPK1 is the phosphorylation of 
AKT1 at Thr308 [32, 33, 84, 277], we evaluated the ability of the chosen chemi-
cals to inhibit the phosphorylation of AKT protein at Thr308. H1299 cells were 
treated with 36 chemicals selected in the previous step (Figure 2A in REF I). 
GSK2334470, a direct inhibitor of PDPK1, was used as a positive control. By 
using Western blot method and pAKT(T308) specific antibody, we identified 12 
compounds from 36, which inhibited AKT1 protein phosphorylation to a 
various degree. The cell cultures treated with these compounds were carefully 
examined for signs of toxicity and 4 chemicals of 12, which did not cause 
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notable changes in cell density and morphology were chosen for further analysis 
(Figure 2A, 2B, Figure S1A-S1D in REF I). 
To find out, whether the selected chemicals were able to inhibit the inter-
action of endogenous AKT1 and PDPK1 proteins, we used in situ proximity 
ligation assay (in situ PLA), which allows specific and sensitive detection of 
protein-protein interactions in their native conditions. PLA is based on the 
immunodetection of the interaction partners with specific primary and oligo-
nucleotide-tagged secondary antibodies. When the proteins of interest interact, 
the in situ PCR generates specific DNA sequence, which is detected by the 
hybridization with fluorescently-labelled DNA oligonucleotides [278]. PLA 
experiment was performed using PC-3 prostate cancer cells, which harbor an 
activated AKT signaling pathway [279]. PC-3 cells were seeded to glass slides 
and incubated with the 4 chemicals selected in the previous step. The number of 
AKT1-PDPK1 interaction sites detected in the cells treated with the NSC156529 
was significantly decreased when compared to PC-3 cells treated with DMSO 
(Figure 2C in REF I). The number of AKT1-PDPK1 interaction sites in cells 
treated with other three chemicals (Figure S2A-S2G in REF I) remained at the 
same level as in control cells. Remarkably, NSC156529 had no significant effect 
on AKT2-PDPK1 and AKT3-PDPK1 interactions, indicating to the specific 
effect of NSC156529 to AKT1-PDPK1 interaction. 
 
 
1.3. AKT1-PDPK1 interaction inhibitor NSC156529 suppresses  
the activity of AKT downstream targets and  
cancer cell proliferation in vitro 
To promote cell-cycle progression and proliferation, active AKT1 protein phos-
phorylates and thereby inactivates a large number of downstream targets [102]. 
Therefore, we next sought to find out, whether the disruption of AKT1-PDPK1 
interaction and reduction of AKT phosphorylation by NSC156529 influences 
the phosphorylation of AKT1 downstream targets, such as GSK3β, FOXO3a, 
BAD and procaspase 9 [121, 280-283]. We found that in PC-3 cells incubated 
with NSC156529 the phosphorylation of the studied AKT1 target proteins was 
significantly decreased when compared to control cells incubated with DMSO 
(Figure 3B in REF I). PDPK1 inhibitor was used as a positive control. The 
basal level of these proteins did not change, with the exception of FOXO3a, the 
overall protein level of which was also reduced. These results indicated that 
NSC156529 treatment inhibited the key biochemical activities of the AKT sig-
naling pathway. 
The main goal of anticancer drugs is to suppress the growth of cancerous 
cells. Therefore, we incubated a selection of immortalized and tumor cell lines 
(Hek293, PC-3, H1299, K07074, and Hep3B) with NSC156529 to verify 
whether this compound is able to inhibit the proliferation of these cells. As a 
result, 96-hour treatment with NSC156529 strongly inhibited the growth of 
selected cell lines, in addition, NSC156529 was more efficient compared to 
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PDPK1 inhibitor which was used as an assay control (Figure S4A-S4D in REF 
I). Importantly, NSC156529 inhibited the growth of PC-3 cells to a larger 
extent than that of primary human fibroblasts, and osteoblasts (Figure 3C in 
REF I). 
 
 
1.4. AKT1-PDPK1 interaction inhibitor NSC156529 suppresses  
the cell proliferation and induces expression  
of differentiation markers in vivo 
To examine whether NSC156529 has an effect on tumor growth in vivo, we 
used a tumor xenograft model (Figure 4A in REF I). Nude mice were injected 
subcutaneously with PC-3 prostate cancer cells, which constitutively expressed 
EGFP.  
The mice bearing a tumor with the median size of 29–32 mm3 were injected 
subcutaneously 3 times a week with NSC156529 at concentrations 1 mg/kg, 
5 mg/kg, 10 mg/kg, or with vehicle only. Tumor size was measured externally 
by using a caliper, and additionally the number of tumor cells was monitored by 
using an in vivo imaging device. The reason for using fluorescent imaging was 
to measure the pure amount of human GFP-expressing xenografts. As the 
human GFP-expressing xenografts are gradually infiltrated by mouse stromal 
cells the caliper measurements might have yielded incorrect results. Tumor 
growth was monitored during the 28-day treatment period. Measurements 
obtained with external caliper were consistent with GFP measurements and 
showed clearly that all used NSC156529 concentrations reduced the tumor 
growth in vivo (Figure 4B and 4C in REF I). Since no adverse side effects, 
such as weight loss, ulcerations, or decline in general health conditions of the 
animals, were observed, and the ALT and AST levels, the biomarkers of liver 
health, stayed within the normal values, it was concluded that in our experi-
mental system NSC156529 did not exert hepatotoxicity (Figure S5 in REF I). 
NSC156529 inhibited AKT pathway in tumor xenografts, as the number of 
cells positive for the pAKT(T308) and the phosphorylated form of BAD protein 
were notably reduced in NSC156529-treated PC-3-GFP xenografts compared to 
control xenografts (Figure 5A and 5B in REF I). The mitotic activity, which 
was detected by the number of pH3-positive cell nuclei, was decreased in 
NSC156529-treated xenografts, indicating that at least in part the inhibition of 
tumor growth was caused by the inhibition of cell proliferation (Figure 5C and 
5D in REF I). The presence of cells, which spontaneously undergo apoptosis, is 
a characteristic feature of malignant neoplasms. To study the role of apoptosis 
in NSC156529-induced tumor growth suppression, we used terminal deoxynuc-
leotidyl transferase nick end labelling (TUNEL) assay, and measured the 
amount of apoptosis markers – fragmented DNA and cleaved caspase-3 (CC3) – 
in tumor xenograft cryosections. The treatment with NSC156529 did not 
significantly increase the number of cells positive for TUNEL nor CC3, which 
indicates that apoptosis did not have a significant role in the growth reduction of 
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mouse tumor xenografts induced by NSC156529 (Figure S6A and S6B in REF 
I). Interestingly, we found that the expression of cytokeratins 15 and 17 (CK15/17) 
(Figure 6A, C, D in REF I) and cytokeratins 8 and 18 (CK8/18) (Figure 6B, 
E, F in REF I) was increased in NSC156529-treated PC-3-GFP xenografts. 
CK15/CK17 label the human prostate basal epithelial cells and CK8/CK18 
expression characterizes the differentiated luminal cells [284]. Since PC-3 cells 
display properties of poorly differentiated prostate cancer [285], increased 
levels of CK15/CK17 and CK8/CK18 indicate that NSC156529 could limit the 
tumor growth at least in part by directing the cancer cells to differentiate. 
 
 
1.5. NSC156529 interacts preferentially with PDPK1 
Interaction inhibition between AKT1 and PDPK1 might be caused by direct 
interaction of NSC156529 either with AKT1 or PDPK1. To study the potential 
interaction between NSC156529 and EYFP-tagged AKT1 or PDPK1 in cell 
lysates we used microscale thermophoresis method (MST). For MST analysis, 
H1299 cells were transfected with either EYFP-tagged AKT1 or PDPK1 
(AKT1–EYFP; PDPK1–EYFP) expressing vectors. Cell lysates containing fluo-
rescently labeled proteins were incubated with serially diluted unlabeled 
NSC156529 and analyzed using a dedicated MST instrument. While NSC156529 
stable binding to AKT1–EYFP could not be detected (Figure S3A in REF I), 
the binding event with the Kd of 981±131 nmol/L was determined for the 
NSC156529 and PDPK1– EYFP interaction (Figure S3B in REF I). These data 
suggested that NSC156529 binds directly to PDPK1. The PDPK1 protein has 
two well-defined docking sites, which are required for the phosphorylation of 
selected PDPK1 targets: ATP pocket and PIF pocket [286]. The potential of 
NSC156529 to bind to these sites was evaluated by docking calculations using 
Glide (Glide, v6.2, Schrodinger, LLC, 2014) and with standard settings 
performed by the previously published PDPK1 crystal structure (PDB ID–
1H1W, [287]). Since the results of the calculations demonstrated no reliable 
binding of NSC156529 to these two sites, NSC156529 most likely interacts 
with PDPK1 at other less structured locations (U. Maran and A.T. García-Sosa; 
personal communication). 
 
2. The inhibition of AKT-PDPK1 interaction efficiently 
suppresses the growth of murine primary  
liver tumor cells (REF II) 
Most frequently upregulated pathways in liver cancer are related to hyper-
activated growth-factor signaling, such as epidermal growth factor (EGF), 
platelet-derived growth factor (PDGF), hepatocyte growth factor (HGF), and 
vascular endothelial growth factor (VEGF), which lead to signal transduction 
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involving cytoplasmic tyrosine kinases like RAS/MAPK, AKT/PI3K/mTOR 
and ERK1/2 pathways [288, 289]. AKT signaling in liver cancer progression 
and the level of AKT activation has been found to correlate with increased 
hepatocellular carcinoma (HCC) recurrence risk [290]. By using a primary 
mouse liver tumor cell line K07074 as a model system, we tested the effect of 
novel chemotherapeutic agents on pathways deregulated in liver tumors.  
 
 
2.1. Increased activity of liver tumor-associated  
pathways in K07074 
K07074 is a primary cancer cell line derived from DEN-phenobarbital induced 
mouse liver tumor tissue. The origin of K07074 cells is not clear. Expression of 
CK19 is characteristic to cholangiocytes, though, the polygonal shape and low 
expression of Hnf4α in K07074 cells might also indicate to hepatocyte origin 
(Figure 1A and 1B in REF II).  
Based on previously published data about active signaling cascades in HCC 
and intrahepatic cholangiocellular carcinoma (ICC) [291, 292], we evaluated 
the gene and protein expression of Wnt, Hedgehog, p53, Notch and AKT1 tar-
gets. Significantly higher gene expression level of Notch pathway target genes 
Hes1, Hey1, Notch3, Trib1, Ccnd1 and the Hedgehog pathway target genes Gli1 
and Gli2 in K07074 cells compared to cultivated hepatocytes (Figure 3A-G in 
REF II) indicates to elevated activity of these pathways. Although the protein 
level of Axin2, a Wnt signaling pathway target gene, was higher in K07074 
cells (Figure 3H and 3I in REF II), the expression of Axin2, was not signifi-
cantly different from that in the control cells (Figure S1 in REF II), suggesting 
that stability of this protein is regulated post-transcriptionally. Immuno-
fluorescence analysis showed that in hepatocytes β-catenin localized primarily 
near cell membrane and in cytosol. In the K07074 cells perimemebraneous  
β-catenin content was decreased and the signal was mainly detected in the 
nucleus (Figure 3J in REF II), which indicated to activated Wnt pathway in 
K07074 cells. The p53 protein level (Figure 3H and 3I in REF II) and the 
expression of p53 target genes p21, CyclinG1 and Gadd45 (Figure S1 in REF 
II) was moderately increased in K07074 cells, though, the expression of p53 
target and its negative regulator Mdm2 and the proapoptotic gene Puma were 
not significantly different from those of control cells. Since sequencing of the 
trp53 gene in K07074 cells revealed no p53 mutations, it is assumed that p53 
transcriptional activity is partially inactivated in K07074 cells.  
Flow cytometry analysis of AKT1 protein expression and phosphorylation 
revealed an increased AKT phosphorylation at its activation sites Thr308 and 
Ser473 in K07074 cells when compared to normal hepatocytes (Figure 3H and 
3I in REF II). In K07074 cells treated with AKT1-PDPK1 interaction inhibitor 
NSC156529 and PDPK1 inhibitor GSK2334470 the phosphorylation of AKT at 
Thr308 but not at Ser473 was decreased (Figure 4A in REF II).  
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Next, the phosphorylation status of AKT target proteins was analyzed by 
Flow cytometry to examine, whether inhibition of Thr308 phosphorylation is 
sufficient to downregulate the AKT pathway activity (Figure 4B in REF II). 
Although Bad protein expression and the level of Bad phosphorylation at 
Ser136 were downregulated in NSC156529 treated cells, the change in phos-
phorylated Bad signal was proportional to the change in Bad protein level. 
Decreased phosphorylation of Gskβ at Ser9 and Foxo at Thr32 indicated to 
downregulated AKT pathway activity in K07074 cells after incubation with 
NSC156529 and GSK2334470. Since studied phosphorylation sites are also 
modified by other Ser/Thr kinases, like serum- and glucocorticoid-inducible 
kinases (SGKs) [217, 293], the treatment with AKT pathway inhibitor NSC156529 
did not completely abolish the phosphorylation of these sites. 
 
 
2.2. AKT and Notch inhibitors efficiently suppress  
the growth of K07074 cells 
Previous results indicated to increased activity of several liver tumor associated 
pathways in K07074 cells, therefore, these cells were treated with Nutlin-3 
(Trp53-Mdm2 interaction inhibitor) [294], Gant61 (Hedgehog pathway 
inhibitor at the level of Gli transcription factors) [26], PNU74654 (Wnt 
inhibitor) [295], GSK2334470 (PDPK1 inhibitor) [296], LY3039478 (Notch 
inhibitor) [297] and NSC156529 (AKT1-PDPK1 interaction inhibitor) [298] to 
study the potential effect of these modulators on K07074 cell growth. 
PNU74654 and Gant61 had no significant impact on K07074 cell growth, and 
Nutlin-3 and GSK2334470 had only a modest impact on cell viability of these 
cells. The moderate effect of Nutlin3 on K07074 growth may be explained by 
the fact that the expression of a subset of p53 target genes, including Mdm2, 
was not activated. On the contrary, Notch inhibitor LY3039478 and AKT1-
PDPK1 interaction inhibitor NSC156529 incubation decreased the number of 
K07074 cells notably during 96-hour treatment (Figure 4C in REF II).  
Since the antitumor efficacies of current therapies are limited, most likely 
because of the high degree of cancer clonal heterogeneity, intratumor genetic 
heterogeneity and cell signal complexity, a shutdown of a single target does not 
necessarily eradicate the cancer and it has been proposed that combined thera-
pies should be used. Therefore, we tested the combined treatment of K07074 
cells with NSC156529 and Hedgehog, Notch or Wnt pathway inhibitors. While 
co-treatment of the cells with a reduced amount (5µM) of NSC156529 and 
working concentrations of Gli and Wnt and Notch inhibitors had no significant 
additive effect (Figure 4D in REF II), the lower NSC156529 concentration 
(3µM) in conjunction with LY3039478 reduced the cell number more 
effectively than either inhibitor alone (Figure 4E in REF II). Conclusively, 
AKT pathway inhibitor NSC156529 is potentially powerful antitumor agent in 
liver cancer treatment and a combination therapy with Notch inhibitors may be 
considered when using suboptimal doses of NSC156529. 
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3. Activated growth factor signaling and increased 
phosphorylation of AKT in small blood vessels  
provide supportive environment for Dupuytren’s 
contracture pathogenesis (REF III) 
Dupuytren’s contracture (DC) is a chronic and progressive transformation of 
connective tissue beneath the palm skin. When the disease progresses, palmar 
fascia within the hand becomes abnormally thick, which severely impairs the 
hand functioning. DC is non-malignant, but it invades locally and has progres-
sive and irreversible nature [299, 300]. Fibrotic lesions in DC of the palmar 
fascia include two distinct structures, the nodule and the cord. Histologically the 
Dupuytren’s nodule is a vascular tissue which comprises numerous myofibro-
blasts (alpha smooth muscle actin expressing fibroblasts). The Dupuytren’s  
cord has a rich connective tissue matrix containing a low density of elongated 
spindle-shaped fibroblasts. Although widely studied, exact pathogenic process 
of the disease is largely unknown. The aim of the study was to shed light into 
the mechanisms and potential molecular targets related to DC pathogenesis.  
 
3.1. Blood vessels in the DC contain proliferating cells and  
endothelial cells with activated phenotype 
It is widely accepted that uncontrolled proliferation of atypical fibroblasts and 
their differentiation into myofibroblasts forms the cellular basis of DC [301]. 
The distribution of proliferative cells in the DC tissue and in normal palmar 
fascia (NPF) samples was visualized by antibodies recognizing proliferation 
marker Ki67 and the myofibroblast marker smooth muscle actin (SMA). While 
the NPF samples were Ki-67-negative (Figure S1A in Additional file 2 in 
REF III), numerous Ki67-positive proliferating cells were concentrated in the 
surrounding area and inside of the SMA-expressing blood vessels in the DC 
tissue (Figure 1A in REF III). Co-staining of DC samples with the SMA and 
endothelial marker von Willebrand’s factor (vWF) verified SMA-positive 
structures as blood vessels (Figure S1B in Additional file 2 in REF III). 
Additional co-staining with antibodies recognizing vWF, pericyte marker 
desmin and Ki67 revealed that vast majority of proliferating cells were located 
in SMA-positive muscular layer of the blood vessels (Figure 1B and 1D in 
REF III), small part of the proliferative cells was located in vWF-expressing 
endothelial compartment (Figure 1C in REF III) and no proliferative desmin-
positive pericytes could be identified (Figure 1E in REF III). Increased num-
ber of proliferating cells near the blood vessels in the DC tissue may indicate to 
activated growth factor signaling in the DC-associated blood vessels. The 
expression of CD90 (Thy-1) and CD105 (endoglin) has been associated with the 
activated state of the endothelial cells in response to growth factor signaling 
[302, 303]. Tissue sample staining revealed that rare small blood vessels found 
in NPF did not contain CD105-expressing cells (Figure S1g in Additional file 
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2 in REF III), however, a number of CD105/CD90 double-positive cell clusters 
were present in DC tissue (Figure 2A, Figure S1E in Additional file 2 in REF 
III). As CD105 expression coincided with the vWF-positive endothelial cells 
(Figure 2B, Figure S1f in Additional file 2 in REF III) and SMA-expressing 
CD90 negative myofibroblasts surrounded the CD90-expressing endothelial 
compartment (Figure 2E, Figure S1H in Additional file 2 in REF III) we 
concluded that endothelium displays an activated phenotype in DC.  
 
3.2. The blood vessels in DC tissue contain cells  
with activated AKT signaling 
Previous studies, which described protein expression profile in the diseased 
palmar fasciae of DC patients indicated the presence of activated AKT pathway 
[304]. While AKT has an essential role in cell proliferation regulation we hypo-
thesized that AKT may contribute to the cell division in vascular/perivascular 
compartment of DC. Since phosphorylated AKT (pAKT) protein is the hallmark 
of activated AKT pathway, DC samples were stained with pAKT(Thr308) 
recognizing antibody to evaluate activation status of AKT protein. pAKT was 
present in all layers of SMA-positive blood vessels and their surrounding 
structures (Figure 3A in REF III). High level of pAKT was also detected in the 
acini and ducts of sweat glands (Figure 3B in REF III), which were sur-
rounded by small blood vessels. AKT kinase is activated by growth factors like 
CTGF, bFGF and IGF-2, which have also been linked to DC pathogenesis [305-
307]. Analysis of CTGF, bFGF and IGF-2 mRNA expression in NPF and DC 
samples revealed that the level of all three growth factors was increased in the 
DC samples compared to NPF (Figure 3D-F in REF III). DC tissue section 
staining with anti-CTGF antibody detected a strong signal in the K15-positive 
acini of the sweat glands (Figure 3G in REF III), while in other parts of the 
DC tissue, including K15-negative sweat gland ducts and blood vessels, CTGF 
was not expressed (Figure 3H in REF III). Although activated AKT was found 
in the acini and ducts, the cells secreting CTGF in acini were not proliferatively 
active (Figure 3I in REF III). IGF-2 expression was distributed all over the DC 
tissue without any preference in respect of small blood vessels (Figure 3J-L in 
REF III). Only the expression of bFGF was confined to the endothelium of the 
small blood vessels (Figure 3M and 3N in REF III) correlating with the 
increased number of proliferative cells in and near the blood vessels. 
Since the composition of the ECM plays a critical role in the regulation of 
cell fate and regenerative potential [32], the presence of specific components of 
the ECM in the areas of DC tissue with increased proliferation was studied. 
Laminin subunits α4, α5, β1, β2, and γ1, which correspond to laminins 411/421 
and 511/521, were enriched in the DC tissue by localizing in the myoepithelial 
compartment of the blood vessel wall (Figure S2A-E in Additional file 3, 
Figure 4 in REF III). These laminins are normal components of the endothelial 
basement membrane [22] and the high laminin content of the DC nodule was 
likely caused by the increased vascularization.  
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DISCUSSION 
Extensive biological and clinical studies during the last decades have identified 
signaling cascades responsible for cancer progression, maintenance and metas-
tasis. AKT signaling pathway, which has important role in cell growth, survival 
and proliferation, has been found to be hyperactivated in many human cancers. In 
addition, activated AKT is an indicator of poor prognosis and resistance to cancer 
therapy. Since protein-protein interactions are responsible for transmitting 
oncogenic signals in pro-oncogenic pathways they have become promising thera-
peutic targets in cancer drug design. Thereof, specific small molecule compounds 
that could block protein-protein interactions in tumors possessing aberrantly 
activated AKT signaling pathway, would be promising tools for cancer treatment. 
The purpose of the first study (REF I) was to discover small-molecule com-
pounds with principally novel mechanism of action that would target the critical 
step in the AKT cascade – the interaction between AKT1 and PDPK1. We took 
advantage of the reversible protein complementation assay, which utilized two 
Renilla luciferase fragments and enabled to detect the interaction between two 
proteins in live cells [275]. The screening and following experiments identified 
one chemical – NSC156529 – which reduced the interaction of ectopically 
expressed and endogenous AKT1 and PDPK1 proteins, decreased AKT1 phos-
phorylation and inhibited tumor cell growth in vitro and in vivo in a tumor 
xenograft model. The detailed molecular mechanism of inactivation by 
NSC156529 is unknown, but based on our data NSC156529 interferes AKT1–
PDPK1 interaction by the direct binding of the compound to PDPK1. 
NSC156529-treated xenografts expressed increased levels of differentiation 
markers, suggesting that inhibiting activity of AKT pathway at the level of 
AKT1–PDPK1 interaction, may possibly open up an alternative way for tumor 
treatment via stimulation of cell differentiation. Since poor differentiation is an 
important hallmark of cancer cells, novel substances that could promote tumor 
cells to differentiate rather than induce cell death is a promising way for cancer 
treatment. To date, the only successful clinical application of differentiation-
based tumor therapy is used in the acute promyelocytic leukemia (APML) 
treatment scheme. All-trans-retinoic acid (ATRA)-based therapy induces granu-
locytic differentiation of APML leukemic blasts, which dramatically improves 
patient survival [308]. Since limited therapeutic effectiveness of conventional 
chemotherapy is often associated with the development of drug resistance and 
systemic toxicity [309], the combined therapy scheme, which consists in addi-
tion a tumor cell differentiation inducing component, could offer a possibility to 
reduce a drug dosage, limit the occurrence of side effects, and decrease the inci-
dence of drug resistance [310, 311]. In vitro cell growth analysis confirmed that 
NSC156529 inhibits the proliferation of the cell lines of variable origin. Since 
hyperactivated AKT pathway has been found in many human tumor types 
[201], the potential use of this chemical should not be limited with one cancer 
type only. In fact, tumor xenograft assays conducted by NCI within the frame-
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work of Developmental Therapeutics Program confirm, that NSC156529 in-
hibits also the growth of B16 melanoma cells and leukemia cell lines L1210 and 
P388 [312]. Although NSC156529 inhibited also the growth of normal human 
fibroblasts and osteoblasts in vitro, the cancer cell proliferation seems to be 
more sensitive to NSC156529 inhibition. In vivo subcutaneous administration of 
the compound was well-tolerated by the animals, since severe symptoms of 
irritation at the injection sites of the skin were not seen. Intraperitoneal 
administration of the compound caused severe irritation indicating to potential 
local toxicity on mucous membranes and endothelium. Because systemic 
administration of this compound to the blood stream was not tested, the rela-
tively low general toxicity observed during our studies might be caused by a 
reduced exposure of NSC156259 to the host organism. Further toxicity studies 
are required to assess and resolve drug administration issues. 
The potential anti-tumor effects of NSC156529 were further elaborated in 
REF II, where primary mouse liver tumor cell line K07074, which was derived 
from DEN-phenobarbital induced mouse liver tumor tissue, was used as a 
model system to test the tumor-suppressive effects of NSC156529 and other 
novel antitumor agents that target cancer-related pathways. Analysis of gene 
and protein expression demonstrated an increased activity of Notch, Hedgehog 
and AKT pathways in these cells. Activation of AKT and Notch pathways, has 
been shown to convert the hepatocytes to cholangiocyte-like cells that act as 
precursors of rapidly progressing ICC [313, 314]. The nuclear localization of β-
catenin found in K07074 cells, commonly refers to the Wnt pathway activation. 
Nevertheless, we were unable to detect an increase in Axin2 mRNA and found 
only a modest increase in Axin2 protein level. Therefore in our model system β-
catenin nuclear localization may appear as a consequence of constitutive AKT 
signaling activity, which phosphorylates and deactivates GSKβ, the kinase 
responsible for β-catenin phosphorylation, cytoplasmic localization and degra-
dation [315]. This could also be the explanation why Wnt pathway inhibitor did 
not have any effect on the growth of K07074 cells. p53 tumor suppressor gene 
inactivation or mutation is a frequent event in tumorigenesis. Accumulation of a 
stable mutant p53 protein is regarded as a hallmark of cancer cells [316]. In 
K07074 cells trp53 gene was not mutated, but the expression of a subset of p53 
target genes including Mdm2 was not activated. This could be the reason why 
in our experiments the inhibitor of p53-Mdm2 interaction – Nutlin3 – was not 
efficient on K07074 cell growth inhibition.  
While the gene and protein expression analysis showed an increased activity 
of several pathways, only AKT and Notch inhibitors efficiently decreased the 
growth of K07074 cells. At higher concentrations, AKT-PDPK inhibitor 
NSC156529 alone was sufficient to inhibit the cancer cell growth, but at subop-
timal concentrations LY3039478 and NSC156529 co-treatment was more effective 
than either compound alone. These results confirm the effective antitumor 
properties of NSC156529 as demonstrated previously by its ability to suppress 
the growth of human tumor cell-line xenografts in nude mice (REF I). 
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Taken together, the small molecular compound NSC156529 is a potent 
inhibitor of AKT1 pathway in tumor cells. NSC156529 reduces AKT activity, 
inhibits the activation of AKT target proteins that are involved in regulating cell 
survival, proliferation, and metabolism, and inhibits the growth of different 
tumor cells in vitro and in vivo. Since treatment with NSC156529 increased the 
differentiation status of cancer cells in in vivo xenograft treatment, this 
compound presents a promising lead for the development of a novel class of 
tumor therapeutics.  
AKT signaling is not only involved in the appearance of malignancies but it 
may also play a role in formation of benign pathologies. Dupuytren’s 
contracture (DC) is a chronic, progressive fibroproliferative disease of the hand, 
which is non-malignant but invades locally and has progressive and irreversible 
nature [317]. Although, uncontrolled proliferation and accumulation of contrac-
tile myofibroblasts is believed to have the central role in DC pathogenesis 
[301], the exact molecular mechanism of the disease is still unclear. The analy-
sis of proliferative cell distribution in the DC tissue (REF III) revealed that 
these were concentrated in the small blood vessels or in their surrounding area, 
primarily in the myofibroblast layer of the blood vessel walls. Previously it has 
been shown that small blood vessels can act as stem cell niches in normal and 
malignant brain tissue [318], therefore, small blood vessels in DC might provide 
a favorable microenvironment for sustaining myofibroblast proliferation. In 
addition, proteomic studies have implicated the proliferation promoting AKT 
pathway in DC pathogenesis [304]. In correlation with these studies, elevated 
levels of phosphorylated AKT, a hallmark of activated AKT signaling, was 
detected in the blood vessels and sweat glands of the DC tissue. The potential 
AKT activating growth factors, including basic fibroblast growth factor (bFGF) 
in the endothelium of the blood vessels, insulin-like growth factor 2 (IGF-2) 
uniformly throughout the nodular tissue and connective tissue growth factor 
(CTGF) in sweat glands near the nodule, were also highly upregulated in DC 
tissue. These observations are supported by previous studies, which suggest that 
IGF-2 has a role in regulating cellular contractility and proliferation in DC 
[307] and that CTGF, a TGF-β target gene and a potent activator of the AKT 
signaling pathway is implicated in the pathogenesis of fibrotic diseases 
including DC [304]. Li et al. reported that in response to FGF signaling, consti-
tutively active AKT induces the transcription of laminin β1 and collagen IV α1 
isotypes and causes their translocation to the basement membrane [319]. Since 
in our study we found active AKT and laminin subunits α4, α5, β1, β2, and γ1 
expressed in the DC tissue, it provides additional support to the hypothesis of 
AKT role in DC pathogenesis. Conclusively, we proposed that small blood 
vessels, which contain increased expression of growth factors and favorable 
extracellular matrix components, form a microenvironment that supports the 
activation of AKT pathway and sustains the persistent myofibroblast prolifera-
tion promoting thereby the progression of DC. 
  
45 
SUMMARY 
Extensive biological and clinical studies during the last decades have identified 
signaling cascades responsible for cancer progression, maintenance and metas-
tasis. AKT-related signaling pathway, which has important role in cell growth, 
survival and proliferation, has been found hyperactivated in many human can-
cers. In addition, activated AKT has been linked also to poor prognosis and 
resistance to cancer therapy. Since protein-protein interactions in tumorigenesis 
promoting pathways are responsible for transmitting oncogenic signals, they 
have become promising therapeutic targets in cancer drug design. Thereof, spe-
cific small molecule compounds that could target protein-protein interactions in 
tumors possessing aberrantly activated signaling pathways, would be promising 
tools in cancer treatment. 
Small molecule library screen utilizing a Renilla luciferase protein comple-
mentation assay (PCA)-based approach, which was aimed to discover AKT1 
and PDPK1 interaction inhibitors, identified one compound – NSC156529 – 
that interacted preferentially with PDPK1, inhibited AKT1 phosphorylation and 
suppressed AKT-mediated signal transduction to several AKT1 substrates. The 
discovered compound efficiently decreased the proliferation of human cancer 
cells in vitro and inhibited tumor growth in a prostate tumor xenograft model in 
vivo. In addition to the reduction in the mitotic activity in NSC156529-treated 
tumors, the tumor cells exhibited a significant increase in the expression of 
prostate differentiation markers, suggesting that the inhibition of tumor growth 
was achieved at least in part through enhanced differentiation of tumor cells 
toward prostate epithelium. In the study with primary mouse liver tumor cell 
line, the AKT-PDPK interaction inhibitor NSC156529 and the Notch pathway 
inhibitor LY3039478, significantly reduced the growth of K07074 cells. 
Although gene and protein expression analysis suggested the presence of acti-
vated Hedgehog, Wnt and p53-related pathways, the inhibitors targeting these 
pathways had little or no effect on K07074 cell growth. In addition, no additive 
effect to NSC156529 could be seen when the cells were co-treated with the 
pathway inhibitors suggesting that the disruption of AKT-PDPK interaction is 
sufficient to inhibit the growth of primary liver tumor cells. 
Dupuytren contracture sample analysis showed that proliferative cells in DC 
nodules localized in the vicinity of small blood vessels, predominantly in the 
myofibroblast layer. The small blood vessels also contained increased levels of 
phosphorylated AKT, which is a hallmark of activated growth factor signaling. 
Respectively, expression of potential activators of AKT signaling, such as 
bFGF, IGF and CTGF, was detected in DC samples. bFGF was expressed in the 
endothelium of the small blood vessels, IGF-2 was present uniformly in the DC 
tissue, and CTGF expressed in the DC-associated sweat gland acini. The blood 
vessels in DC nodules contained also increased amounts of laminins 511 and 
521, which have been previously shown to promote the proliferation and stem 
cell properties of different cell types. Conclusively, DC-associated small blood 
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vessels, with the presence of growth factors and subsequent AKT activation in 
combination with extracellular matrix components, provide a supportive envi-
ronment for myofibroblast proliferation and play an important role in DC patho-
genesis. 
Taken together, the results presented in current thesis demonstrate that tar-
geting AKT related signaling pathway in cancer cells is effective way to sup-
press the growth of cancerous cells. The small molecular compound 
NSC156529 is a potent inhibitor of AKT1 signaling pathway, which reduces 
AKT activity, inhibits the activation of AKT target proteins that are involved in 
regulating cell survival, proliferation, and metabolism, and inhibits the growth 
of tumor cells in vitro and in vivo. NSC156529 is powerful antitumor agent in 
monotherapy, which can also be used at lower doses in combined therapy. Since 
the treatment with NSC156529 increases the differentiation status of cancer 
cells, this compound has an advantage for the development of a novel class of 
tumor therapeutics. In addition, we found that the activated AKT signaling 
might promote the progression of benign hyperproliferative pathology – the 
Dupuytren’s contracture. 
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SUMMARY IN ESTONIAN 
Rakkude paljunemist soodustav AKT signaalirada kui 
potentsiaalne kasvajavastase ravi sihtmärk 
Rakud võtavad väliskeskkonnast vastu mitmesuguseid signaale, näiteks hor-
moonide, kasvufaktorite ja tsütokiinide vahendusel, mis antakse edasi mööda 
signaaliülekande radasid, mõjutades seeläbi nende rakkude paljunemist, eluiga ja 
metabolismiga seotud protsesse ning diferentseerumist. Rakkude jagunemine ja 
suremine on rangelt kontrollitud sündmused, millega tagatakse organismi nor-
maalne funktsioneerimine ja kahjustatud rakkude asendamine uutega. Aja jook-
sul, rakkude vananedes või kokkupuutel kahjulike ühenditega võivad raku DNAsse 
tekkida mutatsioonid, mis omakorda põhjustavad muutusi raku normaalset 
elutsüklit toetavates olulistes signaaliradades. Kasvajarakkude piiramatu kasv on 
väga sageli seotud mutatsioonidega just onkogeenides, mis tekitab nende liigset 
aktiivsust, ja tuumor-supressor valkudes, mis tingib nende geenide väljalülitu-
mise. Vähkkasvaja areng on mitmeastmeline protsess, milles põhiroll on valk-
valk interaktsioonidel kindlates signaaliradades. Seetõttu on kriitilise tähtsusega 
signaaliülekande kaskaadides olevad valk-valk interaktsioonid perspektiivikaks 
sihtmärgiks potentsiaalsete kasvajavastaste terapeutikumide väljatöötamisel. 
AKT kinaas on seriin/treoniinkinaas, mida kirjeldati esmakordselt umbes 25 
aastat tagasi. Praeguseks on selge, et AKT kinaasiga seotud signaalirajal on 
keskne roll normaalsete rakkude füsioloogilistes protsessides nagu näiteks rak-
kude elulemus, rakutsükli edenemine, metabolism, transkriptsioon, valgu sün-
tees, rakkude liikuvus jne. Samal ajal on kontrollimatult aktiivset PI3K/AKT 
signaalirada kirjeldatud väga paljudes inimese tuumorites nagu näiteks maksa-, 
aju-, rinna-, soole ja eesnäärmekasvajates. Lisaks sellele on leitud, et AKT sig-
naalirada on seotud ka kemoteraapia käigus tekkivate resistentsusmehhanismi-
dega ja üldiselt peetakse AKT aktiivsust mõnede kasvajate puhul halva prog-
noosi markeriks. AKT kinaasi keskse rolli tõttu olulistes raku elutsükli 
protsessides ja tema liigse aktiivsuse tõttu kasvajates peetakse AKT valguga 
seotud signaalirada heaks märklauaks kasvajavastaste terapeutikumide 
väljatöötamisel. Praeguseks on avastatud ja kliinilistesse katsetustesse võetud 
juba mitmeid AKT signaaliraja inhibiitoreid, kuid paraku on tugevad 
mittespetsiifilised kõrvaltoimed ja toksilisus takistanud nende edasise 
kasutamise raviskeemides. 
Käesoleva doktoritöö esimese osa põhieesmärk oli leida AKT signaaliraja 
aktiivsust pärssivaid inhibiitoreid, mida võiks kasutada potentsiaalsete kasvaja-
vastaste ravimitena. Otsitavate inhibiitorite täpsem märklaud oli AKT1 ja PDPK1 
valkude omavaheline interaktsioon, mille käigus PDPK1 fosforüleerib AKT1 
valgu – esimene etapp, mis on vajalik AKT1 aktiviseerimiseks. Väikesemoleku-
laarsete ainete skriinimiseks kasutati Renilla lutsiferaasi valgu komplementaar-
susel põhinevat lähenemisviisi. Skriinimine ning sellele järgnenud erinevatest 
meetoditest koosnenud valideerimisprotsess tuvastas ühe kemikaali – NSC156529 
– mis pidurdas erinevat päritolu kasvajarakkude paljunemist nii koekultuuri 
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tingimustes kui in vivo hiire kasvajamudelis. Tuumorirakkude töötlemine 
NSC156529 kemikaaliga mõjutas lisaks AKT kinaasi enda aktiivsusele ka AKT 
signaalirajas allpool asuvate märklaudvalkude aktiivsust, viidates sellele, et antud 
kemikaal mõjutab AKT toimet laiemalt. In vivo kasvajamudelitest eraldatud 
tuumorite analüüsimisel tuvastati, et NSC156529 kemikaaliga töödeldud kasva-
jates oli suurenenud rakkude diferentseerumisele viitavate markerite (tsütokeratiin 
8 ja 18) ekspressioon, millest järeldub, et lisaks suudab NSC156529 tuumori-
rakkude paljunemist pärssida neid diferentseeruma suunates. Käesoleva töö teises 
osas testiti NSC156529 ühendit koos teiste potentsiaalsete kasvajaspetsiifilisi 
signaale pärssivate kemikaalidega hiire primaarse maksakasvaja rakuliinis 
K07074. See mudelsüsteem peegeldab paremini kui püsirakuliinid maksakasva-
jates esinevaid signaaliradade aktiivsuse muutusi. Kuigi geeni- ja valguekspres-
siooni analüüs viitas ka selliste signaaliradade nagu Notch, Wnt, Hedgehog ja p53 
aktiivsusele, leiti et NSC156529 on üksinda piisavalt efektiivne kasvajarakkude 
proliferatsiooni inhibeerimisel. Ainult tingimustes, kus NSC156529 inhibiitorit 
kasutati madalates kontsentratsioonides, andis Notch inhibiitori ja NSC156529 
koos kasutamine rakkude kasvu pidurdamisele tugevama efekti. 
Dupuytreni kontraktuur (DK) on pihukilekõõluse (palmaaraponeuroosi) 
paksenemisega kaasnev sõrme liikuvuse piiratus. Koe tasandil iseloomustab 
seda haigust atüüpiliste müofibroblastide kontrollimatu proliferatsioon. Kuna 
praeguseni on DK täpne molekulaarne mehhanism ebaselge, siis oli käesoleva 
töö kolmanda osa eesmärk kirjeldada täpsemalt paljunevate rakkude asukohta 
DK koes ja selgitada võimalikke selle haiguse tekkimise mehhanisme. DK koe 
analüüsimisel leiti, et aktiivselt jagunevad rakud on koondunud veresoonte 
lähedusse, peaasjalikult neid ümbritsevasse silelihaskihti. Samal ajal oli võrrel-
des normaalse koega DK koe veresoontes ja higinäärmetes suurenenud 
fosforüleeritud AKT valgu hulk, mis võis olla tingitud sellest, et DK koes oli 
suurenenud ka potentsiaalsete AKT signaalirada aktiveerivate kasvufaktorite 
nagu bFGF, IGF ja CTGF tase. Lisaks sisaldasid DK koe veresooned suuremal 
hulgal laminiine 511 ja 521, mida on varasemalt seostatud rakkude tõusnud 
proliferatsiooni ja tüvirakuliste omadustega. Varasemalt on näidatud, et vastu-
seks FGF stimulatsioonile indutseerib aktiivne AKT kinaas laminiin β1 ja 
kollageen IV α1 isotüüpide transkriptsiooni. Seega viitavad antud töö tulemused 
sellele, et DK väikesed veresooned koos suurenenud kasvufaktorite ekspres-
siooni ja aktiivse AKT valgu tasemega loovad soodsa keskkonna müofibroblas-
tide paljunemiseks ning DK haiguse edenemiseks. 
Kokkuvõtvalt, antud töös esitatud tulemused kinnitavad, et AKT kinaasiga 
seotud signaalirada on oluline märklaud kasvajavastaste ravimite väljatöötamisel. 
Kuna leitud AKT1-PDPK1 interaktsiooni inhibiitor NSC156529 on efektiivne 
kasvajarakkude kasvu pärssimisel nii in vitro koekultuuri tingimustes kui in vivo 
hiire tuumori mudelis ning lisaks on NSC156529 kemikaalil rakkude diferent-
seerumist soodustav toime, siis võiks antud ühendit kasutada potentsiaalse vähi-
vastase ravimi väljatöötamisel. Lisaks näitasime, et aktiveeritud AKT signaalirada 
osaleb healoomulise hüperproliferatiivse patoloogia – Dupuytreni kontraktuuri – 
arengus. 
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